DK150690B - Fremgangsmaade og analysepakke til bestemmelse af en komponent i reaktionen mellem et specifikt binder-protein og det tilsvarende bindelige stofved enzym-immunoanalyse - Google Patents
Fremgangsmaade og analysepakke til bestemmelse af en komponent i reaktionen mellem et specifikt binder-protein og det tilsvarende bindelige stofved enzym-immunoanalyse Download PDFInfo
- Publication number
- DK150690B DK150690B DK639871AA DK639871A DK150690B DK 150690 B DK150690 B DK 150690B DK 639871A A DK639871A A DK 639871AA DK 639871 A DK639871 A DK 639871A DK 150690 B DK150690 B DK 150690B
- Authority
- DK
- Denmark
- Prior art keywords
- enzyme
- antibodies
- reaction
- specific binding
- hcg
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
- G01N33/539—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody involving precipitating reagent, e.g. ammonium sulfate
- G01N33/541—Double or second antibody, i.e. precipitating antibody
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/964—Chemistry: molecular biology and microbiology including enzyme-ligand conjugate production, e.g. reducing rate of nonproductive linkage
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/971—Capture of complex after antigen-antibody reaction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/807—Apparatus included in process claim, e.g. physical support structures
- Y10S436/808—Automated or kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/815—Test for named compound or class of compounds
- Y10S436/817—Steroids or hormones
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/815—Test for named compound or class of compounds
- Y10S436/817—Steroids or hormones
- Y10S436/818—Human chorionic gonadotropin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Description
150690 ø
Det er kendt, at en komponent i reaktionen mellem et specifikt binderprotein og det tilsvarende bindelige stof kan bestemmes ved, at man inkuberer en af de omhandlede komponenter forsynet med en markør i en reaktionsblanding, som i det mindste indeholder den anden komponent, 5 og derpå iværksætter en adskillelse mellem den mærkede komponent, som henholdsvis er og ikke er bundet til dens bindingspartner og endelig bestemmer markøren i mindst en af de to fremkomne fraktioner. Fordelingen af den mærkede komponent over de to fraktioner er et mål for den mængde af den søgte komponent, som er til stede i prøven. Der 10 kan beskrives tre systemer, i hvilke den ovennævnte fremgangsmåde kan anvendes, a) antistoffer som specifikke binder-proteiner og de tilsvarende antigener som bindelige stoffer. Stoffer, som kan bestemmes 150690 . 2 på denne måde, er bl, a. proteinhormoner og deres antistoffer eller virus-antigener og deres antistoffer, b) antistoffer som specifikke binder-proteiner og haptener som bindeligt stof. Her defineres hap-tenerne som proteinfri stoffer, der kan reagere med antistoffer uden 5 at være i stand til at inducere dem. Stoffer, som kan bestemmes i et sådant system, er bl.a. steroidhormoner og vitaminer, c) proteiner, som i legemet virker som receptor- eller transport-molekyler som specifikke binder-proteiner og stoffer, som er bundet af dem som binde-lige stoffer. Dette system er f.eks. egnet til bestemmelse af ste-10 roidhormoner, men også af thyroxin og triiodthyronin, vitamin B12, den intrinsicole faktor og det adrenocorticotrope hormon.
De vigtigste punkter i de beskrevne analysemetoder er anvendelsen af en markør og adskillelsen af den mærkede komponent i en fraktion, 15 som er bundet, og en fraktion, som ikke er bundet til den tilsvarende komponent.
Fra beskrivelsen til dansk patentansøgning nr. 5462/71 kendes en fremgangsmåde, ved hvilken der anvendes enzymmærket komponent i forbindel-20 se med en kvantitativ immunologisk bestemmelse. Ved denne kendte fremgangsmåde sker adskillelsen mellem flydende og fast fase ved gelfiltrering, men denne metode er upraktisk og kan ikke give nogen pålidelig og let bestemmelse. Ved metoden kan immunokomponenter kun bestemmes i en koncentration på 50-100 nanogram pr. milliliter.
25
Fra beskrivelsen til dansk patentansøgning nr. 2812/67 kendes endvidere en fremgangsmåde, ved hvilken der gøres brug af uopløseliggjorte antistoffer overfor proteiner eller peptider, som er antigener, i en radio-immun bestemmelse. Radiaktive atomer anvendt som markører er 30 f.eks. 131j, 125^, 14^, 3^, 5?Co Denne fremgangsmåde er kendetegnet ved en høj følsomhed. Imidlertid er denne fremgangsmåde begrænset til institutter, hvor det nødvendige specielle apparatur er tilgængeligt.
Adskillelsesmetoderne kan opdeles på følgende måde: 35 a) Fremgangsmåder afhængige af forskellen i fysiske egenskaber mellem den ikke bundne, mærkede komponent og dens kompleks med bindings-partneren, såsom gel-filtrering, elektroforese, saltudfældning og absorption til dekstran-overtrukket trækul.
40 b. Den såkaldte fastfase-metode, ved hvilken den ene komponent allerede i forvejen er bragt i uopløselig form ved tværbinding eller ved 3 150690 covalent binding eller fysisk adsorption til en fast bærer, c) Den såkaldte dobbelte antistof«metode,ifølge hvilken det dannede kompleks, antigen (eller hapten)«antistof udfældes ved hjælp af antistoffer over for antistoffet i komplekset, hvilken fremgangsmåde 5 kun er kendt fra systemer, i hvilke antistoffer i opløst form kommer i betragtning«
Medens de under a) og c) omtalte fremgangsmåder er relativt komplicerede, lider de under b) omtalte af den ulempe, at en reaktions-10 komponent, når den bringes i uopløselig form, som regel vil mindske sin affinitet til reaktions-partneren. Imidlertid er en høj affinit« vigtig for tilvejebringelse af et følsomt prøvesystem.
Ifølge opfindelsen har man fundet en fremgangsmåde til bestemmelse 15 af en komponent i reaktionen mellem et specifikt binder-protein og det tilsvarende bindelige stof under anvendelse af den kendte bindingsaffinitet af sådanne komponenter indbyrdes, idet man ved bestemmelsen anvender en kendt mængde af et koblingsprodukt af det bindelige stof med et enzym og eventuelt også en kendt mængde af det 20 specifikke binderprotein (i det tilfælde, at det bindelige stof er den komponent, der skal bestemmes), hvilken fremgangsmåde er ejendommelig ved, at man yderligere anvender . uopløseliggjo.rte antistoffer oVér for det-< specif ikke binder-protein,·' og at man efter reaktionen bestemmer enzymaktiviteten i den flydende eller 25 faste fase af reaktionsblandingen. Denne fremgangsmåde muliggør bestemmelse af komponenter, der er til stede i en koncentration på 1-1C nanogram pr. milliliter.
I den foreliggende beskrivelse bruges begreberne conjugat og enzym-30 conjugat synonymt for koblingsproduktet af det bindelige stof og enzymet.
Det bindelige stof kan opdages og bestemmes ved, at man sammenbringer den ukendte prøve eller en fortyndingsserie af samme med en kendt 35 mængde af et conjugat af det stof, der skal bestemmes, og et enzym og med en mængde specifikt binderprotein i afhængighed af den mængde enzym-conjugat, som tilsættes. Derpå tilsættes en mængde, fortrinsvis et overskud af de antistoffer, der er gjort uopløselige over for det specifikke binder-protein, så at hele enzym-conjugatet, som har 40 reageret med binder-proteinet, ved hjælp af dette protein bliver koblet til disse uopløselige antistoffer. Jo mere bindeligt stof der ex 4 150690 til stede i prøven, jo mindre enzym-conjugat vil reagere med det specifikke binder-protein og sluttelig komme i den uopløselige fase. Resultatet bliver, at mere ubundet enzym-conjugat forbliver i den flydende fase og på simpel måde kan bestemmes der. Det specifikke 5 binder-protein kan bestemmes ved, at man inkuberer prøven eller fortyndingsserier af denne med en kendt mængde enzym-conjugat og med en mængde af de over for det specifikke binder-protein uopløselig-gjorte antistoffer. Enzymaktiviteten kan kun finde sted i den uopløselige fase, hvis conjugatet har reageret med det specifikke bin-10 der-protein, d.v.s. jo mere specifikt binder-protein, der er i prøven, jo mindre bundet enzym-conjugat vil forblive i den flydende fase.
Den beskrevne analyse-metodes følsomhed kan varieres ved at ændre mængderne af reagenserne. Imidlertid er den mængde enzym-conjugat, 15 som kan anvendes, begrænset nedefter af kravet om, at dets enzymaktivitet kan måles på rimelig måde, hvorfor analyse-metodens følsomhed har sin begrænsning. Den minimalt målelige enzym-aktivitet er bl. a. afhængig af naturen af det enzym, der anvendes ved koblingen, og af substratets natur og endelig af enzym-reaktionens 20 inkubationstid. Fremdeles indvirker det specifikke binder-proteins affinitet stærkt på bestemmelsens følsomhed. Ved en analyse-metode af høj følsomhed kræves specifikke binder-proteiner med en høj affinitet.
25 Mængderne af de for en bestemmelse nødvendige reagenser må fastlægges ad empirisk vej.
Til bestemmelsen af det bindelige stof må mængden af enzym-conjugatet bestemmes ved hjælp af enzymaktiviteten. Derpå inkuberes denne mængde 30 med en fortyndingsserie af det specifikke binder-protein til bestemmelse af den nødvendige mængde af dette protein. Fortrinsvis vælger man en mængde specifikt binderprotein, som kan binde 50-90% af enzym-conjugatet. Til sidst undersøger man, hvorvidt den ønskede følsomhed så er blevet nået, idet man undersøger en fortyndingsserie af 35 det stof, der skal undersøges ved metoden.
Til bestemmelsen af det specifikke binder-protein må der angående doseringen af enzym-conjugatet tages hensyn til dettes aktivitet, som skal kunne bestemmes med rimelig nøjagtighed.
s 150690
De antistoffer over for det specifikke binder-protein, der er gjort uopløselige, tilsættes fortrinsvis i overskud ved de to bestemmelses-måder. Disses dosering bestemmes ved forudgående forsøg.
5 Denne fremgangsmådes fordele over for de kendte er, at kombinationen af "Dobbelt Antistof" og "Fast Fase"-metoden, i det følgende af bekvemmelighedsgrunde betegnet DASP-metoden, frembyder adskillige fordele over for de kendte fremgangsmåder. Således er udførelsen af den nye fremgangsmåde, d.v.s. tilførsel af uopløseliggjorte anti-10 stoffer over for det specifikke binder-protein, inkubation, centrifugering og måling, meget simpel, doseringen er ofte lettere end ved fast-fase-metoderne, fordi det er tilstrækkeligt at tilsætte et overskud af uopløst materiale, hvorimod man ved fast-fase-metoderne skal bruge en nøjagtigt udmålt mængde af det faste materiale. Frem-15 deles er affiniteten hos binder-proteinet til det bindelige stof ikke svækket af bindingen til bærermaterialet, således som det kan være tilfældet ved fast-fase-metoden. En yderligere fordel over for den sidste fremgangsmåde er den hurtige ligevægt-indstilling hos reaktionen mellem det specifikke binder-protein og det bindelige stof 20 (begge i opløsning). En yderligere fordel består i, at ved DASP- fremgangsmåden kan det uopløseliggjorte antistof, nedenfor betegnet immunoadsorbenten, bruges i ethvert system, i hvilket man bruger antistoffer som specifikke binder-proteiner, forudsat at disse antistoffer er præpareret i de samme dyrearter. På den anden side, for 25 ethvert antigen eller hapten, der skal bestemmes efter fast-fase-metoden, skal antistofferne gøres uopløselige. Den dobbelte antistofmetode er meget følsom over for relativt små ændringer i saltkoncentrationerne, pH og lignende, som gør en vidtgående kontrol af betingelserne nødvendig. Yderligere kræver metoden tilføjelse af 30 "bærer"-γ-globulin og følgelig meget andet antistof til opnåelse af et immunt precipitat. Foruden at være en mere enkel fremgangsmåde fører DASP-metoden, som ikke kræver "bærer"-γ-globulin, til besparelse af materialer. Endelig skal det nævnes, at en dobbelt antistoflignende adskillelse anvendt ved transport- eller receptor-proteiner 35 ikke er mulig, da der ikke kan fremskaffes et "bærer"-protein til dette formål. Fremgangsmåden ifølge opfindelsen frembyder derfor en enestående lejlighed i denne henseende.
Fremgangsmåden ifølge opfindelsen kan let gøres automatisk. Det er 40 principielt muligt at bringe reaktionskomponenterne sammen straks _ t t _ . i _ j . _ -? , » t_ _ i i ^ ^___ ^ r Λ__i · T __ __ i i____ 6 150690 man dog fortrinsvis de uopløselige antistoffer over for det specifikke binder-protein til reaktionsblandingen som det sidste reagens, idet det har vist sig, at bestemmelsen derved får en højere følsomhed.
5
Ved fremgangsmådens anvendelse til bestemmelse af det bindelige stof går man af samme grund hensigtsmæssigt frem på den måde, at man først til prøven sætter det specifikke binder-protein og derpå enzym-con-jugatet og til sidst de uopløselige antistoffer over for det speci-fikke binder-protein.
Det for opfindelsen nødvendige reagens, d.v.s. koblingsproduktet af antigen, hapten eller det bindelige stof med enzymet, kan fremstilles på kendt måde. Disse fremgangsmåder kan også bruges til at bin-15 de et hapten eller et lavmolekulært bindeligt stof til et enzym, forudsat at et af stofferne har en eller flere aminogrupper og det andet en eller flere carboxylgrupper. Hvis det sidste ikke er tilfældet, er det muligt at indføre den ønskede gruppe i molekylet, som skal kobles, ved hjælp af en kendt organokemisk proces. Der kendes 20 også fremgangsmåder til sammenbinding af amino- og carboxylgrupper, eventuelt ved at indføre en bro. Endelig kan komponenter som glutar-aldehyd, difluordinitrodiphenylsulfon og di- og tri-chloro-s-tria= zin ofte anvendes til den omhandlede kobling. Det kan blive nødvendigt at adskille de fremstillede enzymconjugater fra uomdannede stof-25 fer og fra stoffer, som er blevet inaktive. Til dette formål kan man benytte kendte fremgangsmåder, såsom udfældning med organiske opløsningsmidler, gelfiltration og centrifugering ved en vægtfyldegradient .
20 Valget af det enzym, der benyttes i koblingsproduktet, er bestemt ved et antal egenskaber hos enzymet. Naturligvis er det vigtigt, at enzymet er resistent over for koblingen med et andet molekyle, d.v.s. over for ændring af en eller flere aminosyre-sidekæder. Enzymets specifikke aktivitet er også af stor vigtighed. Da en mindre mæng-25 de enzym—conjugat behøver at tilføjes for at opnå en målelig enzympåvirkning, bliver undersøgelsessystemet mere følsomt. Fremdeles bør man foretrække de enzymer, hos hvilke en bestemmelse af aktiviteten kan foretages på en simpel måde, I første række bør man tage de enzymer i betragtning, for hvilke aktiviteten kan béstemmes kolorime-40. trisk, épektrofotometrisk eller fluorimetrisk. Sådanne bestemmelser 7 150690
Man kan bestemme aktiviteten af de, .enzymer kolorimetrisk, som katalyserer en reaktion, ved hvilken der. .opstår eller forsvinder et farvet stof, enten ved den primære eller den sekundære reaktion.
5 Som enzymer, der- kan" anvendes som den enzymatisk; aktive komponent i conjugater, skal nævnes catalase, peroxidase (3-glucoronidase, β-D-glucosidase, β-D-galactosidase, urease, glucose-oxidase, galactose-oxidase og alkalisk phosphatase.
10 Ved afslutningen af reaktionen mellem komponenterne og reagenserne kc man ifølge opfindelsen bestemme enzymaktiviteten i den flydende ellei den faste fase, eller i begge faserne af reaktionsblandingen. Det simpleste er imidlertid at bestemme enzymaktiviteten i den flydende fase, 15
De antistoffer, der er gjort uopløselige over for de specifikke binde proteiner, som også er vigtige reagenser for fremgangsmåden ifølge op findelsen, kan også fremstilles på kendt måde. Antistofferne kan fremstilles, idet man tager et renset præparat af det specifikke bin-20 der-protein eller af de proteiner, som har i det mindste delvis de sa me antigen-egenskaber som det specifikke binder-protein, og så injice rer dette på kendt måde i en anden dyreart end den, fra hvilken man fik det. Det behandlede dyrs serum eller gamma-globulin-fraktionen af dette kan gøres uopløseligt ved kryds-led-forbindelse med sådanne sto 25 fer som glutaraldehyd og chlormyresyre-ethylester eller ved binding t faste bærerpartikler enten fysisk eller adsorptivt eller kemisk ved dannelse af covalente bindinger. Som faste bærere kan anvendes sådanm stoffer som cellulose (ændret eller ikke), agarose, kryds-led-forbundi dekstran, polystyren og lignende. En covalent binding til disse stof· 30 fer af antistoffer kan foretages ved hjælp af sådanne stoffer som car: bodiimider, di- og tri-chloro-s-triaziner, glutaraldehyd, cyanogenbro-mid og f.eks. ved diazotering.
Fordelene ved fremgangsmåden ifølge opfindelsen til bestemmelse af 35 binderprotein opnås, hvis man anvender et overskud af uopløselige ant: stoffer, således at det specifikke binderprotein går helt over i den faste fase.
De former, i hvilke reagenserne kan anvendes, er mangfoldige. Den 40 enzym-conjugerede komponent i reaktionssysternet kan frysetørres eller 8 150690 opløses i en stødpude. Man kan også bruge en fast bærer, f,eks. en papirstrimmel imprægneret med conjugatet. Denne anvendes også til de nødvendige binder-proteiner.
Den uopløselige komponent kan bringes i form af partikler af forskellig størrelse, såsom granuler, flager, stave eller i form af en strimmel af et eller andet bæremateriale.
Opfindelsen angår endvidere en analysepakke til bestemmelse af * et specifikt binder-protein eller det tilsvarende bindelige stof ved den beskrevne fremgangsmåde, hvilken analysepakke er ejendommelig ved at den hovedsagelig indeholder: a) en kendt mængde conjugat af det bindelige stof og et enzym, ’ b) en kendt mængde binder-protein, hvis analysepakken skal anvendes til bestemmelse af det bindelige stof, c) én kendt mængde uopløseliggjorte antistoffer rettede imod det binderprotein, som er tilsat, eller som skal bestemmes, d) et substrat til bestemmelse af aktiviteten af det anvendte enzym.
i
Analysepakken kan fremdeles indeholde de nødvendige yderligere midler til analysens udførelse, såsom reagensglas, pipetter og flasker med opløsninger.
Analysepakken kan særlig hyppigt og med særlig fordel anvendes til opdagelse og bestemmelse af et antigen eller et hapten, og til dette formål indeholder den i hovedsagen: a) en kendt mængde af et conjugat af antigenet eller haptenet og et enzym, b) en tilsvarende mængde af tilsvarende antistoffer, c) en kendt mængde uopløseliggjorte antistoffer, rettede imod de anvendte antistoffer, d) et substrat til bestemmelse af aktiviteten af det anvendte enzym.
Når man anvender sådanne analysepakker til påvisning og bestemmelse af antistoffer, behøver man ikke de under b) nævnte antistoffer.
150690 9
En vigtig udførelsesform for en analysepakke ifølge opfindelsen er én ana-lysepakke til bestemmelse af de gonadotrope hormoner og særlig til bestem' melse af HCG (Human Chorionic Gonadotropin) som et middel til bestemmelse 5 af graviditet allerede på et meget tidligt stadium, hvilken analysepakke er ejendommelig ved, at den består af en beholder, der som væsentlige bestanddele i lyofiliserede lag indeholder: a) en bestemt mængde af et HCG-conjugat og et enzym, f.eks. HCG-peroxidase b) en bestemt mængde anti-HCG, c) en bestemt mængde uopløseliggjorte antistoffer oyer for anti-HCG sammei med et substrat til bestemmelse af enzymaktiviteten af det resterende HCG-enzym i den flydende fase.
Ved tilsætning af en vis mængde urin fra en formodet gravid kvinde, til 15 denne analyseblanding og ved at inkubere urinen med disse bestanddele dannes der en blanding af uopløseligt stof, idet den øvrige del indeholder det tilbageblevne opløselige HCG-enzym-conjugat. Mængden af det sidste afhænger af mængden af HCG i den undersøgte urin. Ved bestemmelse af enzymaktiviteten hos dette tilbageblevne HCG-enzym-conjugat kan man 20 fastslå, om urinen skyldes en gravid kvinde eller ej.
En fremgangsmåde, der fortrinsvis anvendes ved bestemmelsen af enzymaktiviteten, består i, at man bringer et indikator-papir imprægneret med enzymreagenser, f.eks, hvis der bruges en peroxidase, en H„09-forsyner så- 25 ^ ^ som urinstof-EL^,med et farvereagens såsom o-tolidin.
Ved korrekt valg af mængderne af hvert af reagenserne bliver det muligt at fastslå graviditet allerede på et meget tidligt stadium og på en simpel, hurtig og meget pålidelig måde, som kan udføres af en ikke opøvet 30 person.
150690 10
Eksempel 1.
Bestemmelse af det menneskelige chloriongonadotropin (HCG).
5 a) Fremstilling af HCG-HRP.
5 mg HCG og 20 mg peberrods-peroxidase (HRP) opløses i 2 ml 0,05 M phosphat-stødpude med pH-værdien 6,2. Efter tilsætning af ko μΐ 25$ glutaraldehyd-ορløsning rystedes “blandingen i 2 timer ved stuetemperatur. Efter 5 minutters centrifugering ved 250 g fraktioneredes væsken over Sephadex G-200 i 0,05 M phosphat= stødpude med pH-værdien 6,2. Fraktionerne, hos hvilke den højeste enzymaktivitets $ var bundet af antistoffer overfor HCG brugtes under analysen.
15 b) Fremstilling af antistoffer overfor HCG.
Antistoffer overfor HCG indiceredes i kaniner som angivet af Schuurs et al. Acta Endocr. (Kbh) 59j 120,(1968).
c) Fremstilling af antistoffer overfor kanin-y-globulin.
2q Kanin-Y-globulin isoleredes fra normalt kanin-serum ved udfældning med l8$ w/v fast natriumsulfat. Antistoffer overfor dette fremstilledes ved immunisering af et får i overensstemmelse med følgende skemai 25 dag mængde Freud's adjuvans injektionsmåde 0 o,5 mg + intramuscular 1^· o,5 mg + intramuscular 28 1 mg + intramuscular b2 1 mg - intravenøs 3Q 56 1 mg - intravenøs den 70.dag blev fåret åreladt.
d) Fremstilling af immunoadsorbent-eellulose /får-anti-(kanin-γ-globu= 35 lin)7.
γ-globulinfraktionen af fåre-serumet beskrevet under c) fremstilledes ved udfældning med 165¾ w/v fast natriumsulfat. Efter vaskning optoges udfældningen i så meget 0,05 M borat-stødpude med pH-værdien 8,6, at den fremkomne proteinkoncentration udgjorte 10 mg/ml.
4Q 350 mg m-aminobenzyloxymethylcellulose opslemmedes i 50 ml destilleret 11 15069¾ vand og diazoteredes ved tilsætning af 10 ml 30$ saltsyre og dråbevis tilsætning af 10 ml 10$ NaDiK^-opløsning ved 0°C. Op-slemningen centrifugeres. Den vaskedes, og bundfaldet resuspendere-des i *+3 ml 0,05 M natriumborat med pH-værdien 8,6, derpå tilsattes 5 7 ml af den fremstillede γ-globin-opløsning. Blandingen omrørtes i 26 timer ved å-°C, hvorpå den centrifugeredes og vaskedes med 0,02 M phosphat-stødpude med pH-værdien 6,0.
e) Bestemmelse af HCG
10 Der fremstilledes en fortyndingsserie (32 -16-8-^-2-1-o,5-IU/ml) af HCG i 0,02 M phosphat-stødpude med pH-værdien 6,0, som indeholdt 2$ v/v normalt fåreserum.
0,5 ml af hver af de HCG-indeholdende prøver inkuberedes med 0,1 ml kanin-(anti-HCG)-serum og 0,1 ml HCG-KRP-conjugat, begge i passen-15 de fortynding i eii halv time’ved stuetemperatur. Derpå tilsatte 0,3 ml af immunoadsorbenten (10 mg/ml) fremstillet ifølge d),og den fremkomne blanding omrørtes i en time ved stuetemperatur. Efter centrifugering bestemtes enzymaktiviteten: resten ved at blande 0,5 ml .
af denne væske med 1,5 ml substrat (10μ1 30$ ^.$2 °& 20 mg 5-amino--20 salicylsyre i 150 ml 0,02 M phosphatstødpude med pH-værdien.6,0), og efter 30 minutter ved 25°C måltes ekstinctionen ved 1+60 mm.
På denne måde påvistes det, at det var muligt at opdage en HCG-koncentration fra 0,5 til lIU/ml i prøven. Ved denne metode kunne man også undersøge urinprøver. Undersøgelsen er derfor egnet til 25 en graviditetsprøve. Forholdet til en eksisterende undersøgelsesmetode, en hæmaglutinations-·inhibitions-prøve var god. Det påvistes muligt at forøge systemets følsomhed ved anvendelse af en pre-incubation. Her incubereres prøven først med antiserumet og derpå tilsattes HCG-HRP-conjugatet.
30
Eksempel II.
Bestemmelse af insulin og anti-insulin.
a) fremstilling af insulin-(glucose-oxidase).
35 Der opløstes 5 mg grise-insulin af 25 mg glucose-oxidase i 2 ml 0,05 M phosphat-stødpude med pH-værdien 6,5. Hertil sættes 5 μΐ glutaraldehyd-opløsning, hvorefter blandingen rystedes i 90 minutter ved stuetemperatur. Blandingen fraktionereres over Sephadex 150690 12 G-200 i 0,05 M phosphat-stødpude med pH-værdien 6,5.De .fraktioner, af hvilke den højeste procentiske enzym-aktivitet kunne hindes af antistoffer overfor insulin, anvendtes ved analysen 5 b) Fremstilling af antistoffer overfor insulin.
Man ggv·' 10 marsvin &n;- ugentlig intramuskulær injektion med 1 mg grise-insulin i fuldstændig Freud's adjuvans gennem en periode på ^+-8 uger. Efter 10 ugers hvile gav man dyrene yderligere 1 mg insulin ved intravenøs injektion uden adjuvans. To uger senere blev 10 dyrene åreladt. Man modarbejdede den tilstødende hypoglycæmi ved intraperional administration af glucose.
c) Fremstilling af antistoffer ' overfor. maxsvin-γ-globulin.
Der . fremstilledes marsvin-Y-globulin ved tilsætning af 1 15 volumen ^mættet ammoniumsulfat-opløsninq til 2 volumen marsvine- serum. Den fremkomne udskillelse vaskedes to gange med 33i° mættet ammoniumsulfat-opløsning, hvorefter den optoges i en fysiologisk saltopløsning. Derpå immuniseredes et får med voksende doser af det fremstillede γ-globulin: 0,5 - 1 og 2 mg. Injektionerne blev 20 givet hver anden uge, idet immunogenet var blandet med fuldstændig
Freud's adjuvans. To uger efter den sidste injektion gaves der yderligere 2 mg γ-globulin i en fysiologisk saltopløsning, og en uge senere blev dyret åreladt.
25 d) Fremstilling af uopløselige antistoffer overfor marsvin-Y-globulin.
10 g mikrokrystallinsk cellulose aktiveredes ved, at det under omrøring sattes til H00 ml 2,5$ w/v CWBr-opløsning, hvorefter pH-værdien øgedes til 10,5 nied 1 N NaOH-opløsning, idet denne værdi opret 30 holdtes i 2 minutter. Derpå vaskedes cellulosen med isvand og med 0,1 M NaHCOy Der tilsattes 1,6 g Na^SO^ til 10 ml fåre-anti( marsvin.-γ-globulin) -serum. Efter en times omrøring ved stuetemperatur centrifugeres udfældningen. Der vaskedes to gange med 20 ml 16$ w/v Na^O^-opløsning, hvorefter det optoges i 10 ml 0,1 M NaHCO^-35 opløsning. Den aktiverede cellulose blandedes med *+0 ml 0,1 M NåKCO^- opløsning og de 10 ml γ-globulin-opløsning. Denne suspension om-rørtes i ^0 timer ved ^°0 og vaskedes efterhånden to gange med 150690 13 500 ml 0,5 M NaHCO^j to gange med 500 ml 0,05 M citrat af pH-værdien 1,1 og to gange med 500 ml 0,05 M phosphat af pH-værdien 6?5 5 e) Bestemmelse af antistoffer overfor insulin.
0,1 ml insulin-(glucose-oxidase) inkuberedes i passende fortynding med 0,*+ ml af en fortynding s serie af en marsvin-anti-insulin-serum i timer. Fortynding s s er i en foretoges med 0,05 M phosphat-stødpude med pH-værdien 6,0. Derpå tilsattes 0,3 ml immunoadsorbent 10 (15 mg/ml) og 0,2 ml stødpude, og blandingen omrørtes natten over ved *f°C. Efter centrifugering bestemtes enzymaktiviteten'af den resterende opløsning ved incubering af 0,5 ml af denne med 2,5 ml substrat i 30 minutter, hvorpå man målte ekstinetionen ved *+60 nm. Substratet indeholdt 50 mg glucose, 10 μg peroxidase og 1 mg 15 5- amino salicyl syre pr. 2,5 ml 0,05 M phosphat-stødpude med pH-værdien 6,0.
Med dette system kunne antistofindholdet i de forskellige slags serum sammenlignes. Som referencepunkt valgtes den serumfortynding, hvor 5o5 af den totale kombinerbare enzymaktivitet er bundet.
20 f) Bestemmelse af insulin.
0,2 ml af en fortyndingsserie af insulin incuberedes i 2 timer med 0,1+ ml anti-insulin-serum i en sådan fortynding, at den kunne binde 60$ af det tilsatte enzym-conjugat. Derpå tilsattes 0,1 ml 25 insulin-(glucose-oxidase) · des i timer. Endelig tilsattes 0,3 ml immunoadsorbent (15 mg/ml). Blandingen omrørtes natten over ved H°C. Efter centrifugering måltes enzymaktiviteten i resto. løsningen som angivet under e). Bestemmelsens følsomhed, som afhænger af det anvendte antiserum, lig-30 ger indenfor nanogram-ordenen: 20-100 mg/ml, d.v.s* 0,5-2,5 mU/ml.
Eksempel III.
Bestemmelse af oestradiol.
35 a) Fremstilling af oestradiol-17-succinyl-HRP.
50 mg oestradiol-17-hemisuceinat og 0,08 ml tri-n-butylamin opløstes i 2,5 ml dioxan. Til den kolde (2°C) opløsning sattes 15 Hl isobutylchlorocarbonat. Efter 3o minutter blandedes denne opløsning
lif T5069Q
med 100 mg peberrodsperoxidase (HRP) i 7?5 ml af en dioxan/vand-blanding (2:3)5 som var indstillet til en pH-værdi på 9j5 med natriumhydroxid. Opløsningen omrørtes i *+ timer ved 2°C og dialyseredes derpå i 18 timer. Udfældningen, der var dannet efter at dialysatets 5 pH-værdi var indstillet til *+,6, centrifugeredes fra, vaskedes og op toges i 5 ml destilleret vand, som var indstillet til en pH-værdi på 8. Stoffet rensedes yderligere ved to ganges udfældning med 10 ml acetone. Det færdige produkt optoges i 10 ml 0,05 M piiospliat-stødpude med pH-værdien 738.
10 b) Fremstilling af østradiol-17-suecinyl-BSA.
Fremstillingen foretoges ifølge den blandede anhydrid-metode, som er angivet i eksempel Illa. Denne fremstilling foretoges, idet man gik ud fra 100 mg østradiol-17-hemisuccinat og 150 mg hornkvægsse-15 rum-albumin (BSA).
c) Fremstilling af antistoffer overfor østradiol.
Man injicerede et får en gang i *+ uger med k mg østradiol-17-succinyl-BSA i fuldstændig Freund's adjuvans. Med regelmæssige mellem 20 rum udtoges der blod fra dyret. Serumet absorberedes med BSA, som var gjort uopløseligt.
d) Fremstilling af antistoffer overfor fåre-Y-globulin.
Der fremstilledes fåre-Y-globulin som angivet i eksempel I, men nu 25 med 16$ w/v natriumsulfat. Man immunicerede så kaniner med denne fåre-Y-globulin efter følgende skema:
Dag mængde Freund's ad.iuvans innektionsmåde 0 200 ^g + intramuskulær 30 lb *+00 μg + ' " 28 800 μg + " b2 800 ug - intravenøs o c 2 Uger efter den sidste injektion blev dyret åreladt.
i5 150690 e) Fremstilling af immunoadsorbenten /kanin-anti (-fåre-Y-globulin)_7-cellulose.
Y-Globulinfraktionen fra de antisera, der er angivet under d), fremstilledes ved udfældning med 18$ w/v Wa^SO^. Det fremkomne produkt 5 kobledes med cellulose efter Gurvich's metode, angivet i eksempel I.
f) Bestemmelse af østradiol.
Immunreaktionen udførtes i 0,02 M phosphat-stødpude med pH-værdien 6,0, som indeholdt 2$ BSA.
10 5 ml af prøven blandedes med 0,1 ml af fåre-anti-østradiolserumet i den ønskede fortynding. Efter 30 minutters inkubation ved stuetemperatur tilsattes 0,1 ml østradiol-17-succinyl-HRP i en passende fortynding, hvorefter der fulgte en anden 30 minutters inkubation 15 ved stuetemperatur. Derpå tilsattes Qf3 ml immunoadsorbent"su" spension (30 mg/mll, og blandingen omrørtes i 2 timer ved stue" temperatur. Derpå adskiltes den flydende og den faste fase ved centrifugering. Enzymaktiviteten i den flydende bestanddel måltes som angivet i eksempel I. Man kunne anvende fåre-anti-østradiol-20 serumet i fortyndinger fra 1:1600 til 1:12800 i afhængighed af kva liteten af det anvendte østradiol-17-succinyl-HRP. Ved en fortynding af 1:12800 af antiserumet kunne en østradiol-koncentration på 10 ng/ml opdages i prøven. Østradiol og østron viste en krydsreaktion i dette system.
25
Eksempel IV
Bestemmelse af cortisol og corticoid-bindende globulin.
a) Fremstilling af cortisol-21-(galaktose-oxidase).
30 Man koblede 50 mg cortisol-21-hemisuccinat og 100 mg galaktose- oxidase ved hjælp af den blandede anhydrid-teknik angivet i eksempel Illa.
b) Corticoid-bindende globulin (CBG) isoleredes fra human serum ved 35 hjælp af successions-kromatografi over DEAE-cellulose og hydroxyl- apatit.
Antistoffer overfor dette fremstilledes ved injicering af kaniner i 1^—dagesmellemrum med 500 Pg CBG i fuldstændig Freund's adjuvans.
Efter 3 måneder injiceredes dyrene med 1 mg CBG, og 2 uger senere i6 150690 c) γ-Globulin- fraktionen af anti-CBG- serum koblede s til m- aminobenzy1= oxymethylcellulose som angivet i eksempel III.
d) Bestemmelse af cortisol.
5 0,5 nil af en prøve, der indeholdt cortisol (standard-opløsning) ekstraheredes med 2 x 3 nil methylenchlorid. Den sammenbragte ekstraktionsvæske inddampedes til tørhed. Residuenten optoges i 0,5 ml 0,05 M phosphat-stødpude med pH-værdien 6,2. Derpå blandedes med 0,1 ml af en opløsning af CBG i den samme stødpude i en passende 10 koncentration, og der inkuberedes i 30 minutter ved h°C. Derpå tilsattes 0,1 ml cortisol-21-(galaktose-oxidase), også i passende fortyndingjOg 0,3 ml af immunoadsorbenten, der fremstilledes under c), med en koncentration af 5 mg/ml. Den fremkomne blanding omrør-tes i 2 timer ved ^°0 og derpå centrifugeredes, hvorefter enzymakti-15 viteten måltes i restvæsken. I den anledning tilsattes 0,5 nil af samme til 1,5 ml substrat bestående af 100 mg D-galaktose, 20 mg 5-aminosalicylsyre og 10 Mg peroxidase i 150 ml 0,02 M phosphat-stødpude med pH-værdien 6,0. Efter 30 minutter måltes ekstinctionen ved *+60 nm. Ved anvendelse af en CBG-koncentration på O,1* Mg/ml og 20 'så meget cortisol-21-(galaktose-oxidase), at 80$ af enzym-konjugatet var bundet til immunoadsorbenten, uden at der tilføjedes steroider, viste det sig muligt at bestemme mængder af fra 3 til 30 ng cortisol e) Bestemmelse af CBG var også mulig med de angivne reagenser. Fra en 25 fortyndingsserie af transcortin, rækkende fra O til 1280 ng/ml in kuberedes 0,5 ml i 15 minutter med 0,2 ml cortisol-21-(galaktose-oxidase) i passende fortynding. Derpå tilsattes 0,3 ml immunoad-sorbent-suspension (5 mg/ml), og blandingen omrørtes i 15 minutter. De to inkubationer holdtes ved Η-°ϋ. Derpå måltes enzymaktiviteten 30 i restvæsken som under d) c Analysemetodens følsomhed viste sig at være 50 ng/ml).
Eksempel V
35 I en flaske lyofiliseredes efterhånden følgende reagenser i adskilte lag: 0,3 ml af immunoadsorbent-suspensionen (10 mg/ml) som angivet i eksempel la.
40 2) 0,1 ml af en Ifo mannitol-opløsning.
Claims (2)
1. Fremgangsmåde til bestemmelse af en komponent i reaktionen 2Q mellem et specifikt binder-protein og det tilsvarende bindelige stof under anvendelse af den kendte bindingsaffinitet af sådanne komponenter indbyrdes, idet man ved bestemmelsen anvender en kendt mængde af et kob'lingsprodukt af det bindelige stof med et enzym og eventuelt også en kendt mængde af det specifikke binderyprotein 25 (i det tilfælde, at det bindelige stof er den komponent, der skal bestemmes), kendetegnet ved, at man yderligere anvender uopløseliggiorte antistoffer over for det specifikke binder-protein, og at man efter reaktionen bestemmer enzymaktiviteten i den flydende eller den faste fase af 3Q reaktionsblandingen. 1
2 Fremgangsmåde ifølge krav 1, kendetegnet ved, at man tilsætter de uopløselige antistoffer over for det specifikke binder-protein til reaktionsblandingen som det sidste reagens. 35 2 Fremgangsmåde ifølge krav 2 til bestemmelse af det bindelige stof, kendetegnet ved, at man først til prøven sætter det specifikke binder-protein og derpå enzymconjugatet og til sidst de uopløselige antistoffer over for det specifikke binder-
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL707018838A NL154599B (nl) | 1970-12-28 | 1970-12-28 | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
NL7018838 | 1970-12-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
DK150690B true DK150690B (da) | 1987-05-25 |
DK150690C DK150690C (da) | 1988-06-06 |
Family
ID=19811894
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK639871A DK150690C (da) | 1970-12-28 | 1971-12-28 | Fremgangsmaade og analysepakke til bestemmelse af en komponent i reaktionen mellem et specifikt binder-protein og det tilsvarende bindelige stof ved enzym-immunoanalyse |
Country Status (20)
Country | Link |
---|---|
US (1) | US3839153A (da) |
JP (3) | JPS5834783B1 (da) |
AT (1) | AT320145B (da) |
AU (1) | AU467394B2 (da) |
BE (1) | BE777309A (da) |
BR (1) | BR7108553D0 (da) |
CA (1) | CA964560A (da) |
CH (1) | CH557030A (da) |
DE (1) | DE2164768B2 (da) |
DK (1) | DK150690C (da) |
EG (1) | EG11604A (da) |
ES (1) | ES398372A1 (da) |
FI (1) | FI54034C (da) |
FR (1) | FR2120835A5 (da) |
GB (1) | GB1348938A (da) |
IL (1) | IL38371A (da) |
IT (1) | IT965020B (da) |
NL (1) | NL154599B (da) |
SE (1) | SE398557B (da) |
ZA (1) | ZA718332B (da) |
Families Citing this family (854)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE31006E (en) * | 1968-09-24 | 1982-08-03 | Akzona Incorporated | Process for the demonstration and determination of reaction components having specific binding affinity for each other |
NL171930C (nl) * | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
US3790447A (en) * | 1972-07-05 | 1974-02-05 | Abbott Lab | Streptococci diagnostic method |
DE2333434C3 (de) * | 1973-06-30 | 1978-04-06 | Istvan D. Dr. 5024 Pulheim Bartos | Verfahren zur Durchführung serologischer Untersuchungen nach dem Prinzip der Komplementbindungsreaktion und gebrauchsfertige Schnelltestpackung hierfür |
US4239746A (en) * | 1973-06-30 | 1980-12-16 | Dezso Istvan Bartos | Complement fixation test employing reactants in a disposable package |
US3935074A (en) * | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
GB1508132A (en) * | 1974-05-20 | 1978-04-19 | Technicon Instr | Analysis of biological fluids |
US4040907A (en) * | 1974-06-20 | 1977-08-09 | Syva Company | Iodothyronine enzyme conjugates |
US4001087A (en) * | 1974-10-10 | 1977-01-04 | The United States Of America | Affinity labelling enzymes with esters of aromatic sulfonic acids |
FR2288312A1 (fr) * | 1974-10-14 | 1976-05-14 | Pasteur Institut | Procede de dosage immunoenzymatique de la progesterone |
US4002532A (en) * | 1974-10-21 | 1977-01-11 | Weltman Joel K | Enzyme conjugates |
SE388694B (sv) * | 1975-01-27 | 1976-10-11 | Kabi Ab | Sett att pavisa ett antigen exv i prov av kroppvetskor, med utnyttjande av till porost berarmaterial bundna eller adsorberande antikroppar |
NL7501215A (nl) * | 1975-02-01 | 1976-08-03 | Akzo Nv | Methode voor het aantonen en bepalen van een antigeen of antilichaam. |
US4629688A (en) * | 1975-04-28 | 1986-12-16 | Miles Laboratories, Inc. | Homogeneous specific binding assay method |
US4230797A (en) * | 1975-04-28 | 1980-10-28 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a coenzyme as label |
USRE32696E (en) * | 1975-09-04 | 1988-06-14 | Akzona Incorporated | Enzymatic immunological method for determination of antigens and antibodies |
US4474878A (en) * | 1975-09-29 | 1984-10-02 | Cordis Laboratories, Inc. | Sandwich EIA for antigen associated with hepatitis |
US4642285A (en) * | 1975-09-29 | 1987-02-10 | Diamedix Corporation | Sandwich EIA for antigen |
SE7610683L (sv) * | 1975-09-29 | 1977-06-10 | Cordis Corp | Metod for bestemning av nervaron av ett antigen associerat med hepatit |
JPS5272284A (en) * | 1975-12-12 | 1977-06-16 | Dainippon Pharmaceutical Co | Enzymeeimmunoassay reagent |
US4045384A (en) * | 1976-07-23 | 1977-08-30 | The Dow Chemical Company | Method for forming an amide bond between a latex and protein |
GB1549069A (en) * | 1976-12-10 | 1979-08-01 | Erba Farmitalia | Enzyme linked immunoassay |
US4200690A (en) * | 1976-12-16 | 1980-04-29 | Millipore Corporation | Immunoassay with membrane immobilized antibody |
US4407943A (en) * | 1976-12-16 | 1983-10-04 | Millipore Corporation | Immobilized antibody or antigen for immunoassay |
JPS5399319A (en) * | 1977-02-09 | 1978-08-30 | Hidematsu Hirai | Novel qualitative and quantitative detecting method and detecting body for antgenic substance |
IT1114861B (it) * | 1977-05-12 | 1986-01-27 | Sclavo Inst Sieroterapeut | Metodo per la determinazione del contenuto di costituenti di fluidi biologici e mezzi adatti allo scopo |
AU531777B2 (en) * | 1978-04-05 | 1983-09-08 | Syva Co. | Label/solid conjugate immunoassay system |
US4233402A (en) * | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
US4492751A (en) * | 1978-04-10 | 1985-01-08 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing an enzyme substrate as label |
US4318980A (en) * | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
US5605800A (en) * | 1978-04-13 | 1997-02-25 | Institut Pasteur | Method of detecting and characterizing a nucleic acid or a sequence of the latter, and enzymatic reactant for the application of this method |
FR2422956A1 (fr) * | 1978-04-13 | 1979-11-09 | Pasteur Institut | Procede de detection et de caracterisation d'un acide nucleique ou d'une sequence de celui-ci, et reactif enzymatique pour la mise en oeuvre de ce procede |
JPS5510590A (en) * | 1978-05-04 | 1980-01-25 | Wellcome Found | Enzyme immunity quantity analysis |
JPS5539702A (en) * | 1978-08-30 | 1980-03-19 | Takeda Chem Ind Ltd | Method of measuring enzyme immunity of pancreas glucagon |
FR2440555A1 (fr) * | 1978-10-31 | 1980-05-30 | Maes Roland | Perfectionnements aux procedes de determination de substances montrant entre elles des affinites de liaison specifiques, par des tests faisant intervenir une phase solide |
US4260678A (en) * | 1979-02-23 | 1981-04-07 | Corning Glass Works | Determining creatine kinase isoenzmes via immobilized antibody-isoenzyme complexes |
JPS55152459A (en) * | 1979-05-18 | 1980-11-27 | Yamasa Shoyu Co Ltd | Method and reagent for measuring quantity of cyclic nucleotide |
US4289748A (en) * | 1979-05-31 | 1981-09-15 | United States Of America | Ultrasensitive enzymatic radioimmunoassay method |
DE2930706A1 (de) * | 1979-07-28 | 1981-02-05 | Medac Klinische Spezialpraep | Verfahren zum nachweis von erregerspezifischen antikoerpern |
US4299916A (en) * | 1979-12-26 | 1981-11-10 | Syva Company | Preferential signal production on a surface in immunoassays |
US4394391A (en) * | 1980-02-19 | 1983-07-19 | Thorell Jan Ivan | Radioimmunoassay reagents |
US4322495A (en) * | 1980-03-11 | 1982-03-30 | Minnesota Mining And Manufacturing Co. | Immunoassay |
SE8003732L (sv) * | 1980-05-19 | 1981-11-20 | Pharmacia Diagnostics Ab | Sett vid bestemningsmetoder involverande biospecifika affinitetsreaktioner |
EP0040728A1 (en) * | 1980-05-19 | 1981-12-02 | Pharmacia Diagnostics Ab | An improvement in and relating to assaying methods involving biospecific affinity reactions |
JPS5714748A (en) * | 1980-07-01 | 1982-01-26 | Dainippon Pharmaceut Co Ltd | Kit for quantitative determination of valproic acid and its method for quantitative determination |
US4323647A (en) * | 1980-10-15 | 1982-04-06 | University Of Miami | Steric hindrance enzyme immunoassay |
DE3048884A1 (de) * | 1980-12-23 | 1982-07-15 | Boehringer Mannheim Gmbh, 6800 Mannheim | Verfahren zur enzymimmunobestimmung in heterogener phase |
ES8307897A1 (es) * | 1981-04-13 | 1983-08-01 | Hoechst Co American | Un metodo de determinar la presencia de un antigeno en un medio liquido sospechoso de contenerlo. |
US4604365A (en) * | 1981-06-02 | 1986-08-05 | Electro-Nucleonics, Inc. | Immunoprecipitation assay |
WO1982004323A1 (en) * | 1981-06-02 | 1982-12-09 | O Neill Sean | Immunoprecipitation assay |
US4506009A (en) * | 1982-03-30 | 1985-03-19 | University Of California | Heterogeneous immunoassay method |
US4535057A (en) * | 1982-07-26 | 1985-08-13 | Amf Incorporated | Immunoassay employing monoclonal herpes simplex antibody and biotin-avidin detection system |
US4515890A (en) * | 1982-11-08 | 1985-05-07 | Abbott Laboratories | Immunoassay of terminal deoxynucleotidyl transferase |
US4650751A (en) * | 1983-04-29 | 1987-03-17 | Technicon Instruments Corporation | Protected binding assay avoiding non-specific protein interference |
US4778752A (en) * | 1983-10-11 | 1988-10-18 | Scripps Clinic And Research Foundation | Receptors specific for hapten-modified self proteins |
EP0229767B1 (en) * | 1985-03-18 | 1990-09-26 | Royal Free Hospital School Of Medicine | Improvements relating to the detection of viruses and antibodies |
JPS62148857A (ja) * | 1985-12-24 | 1987-07-02 | Toyo Soda Mfg Co Ltd | 免疫測定用材料の製造方法 |
EP0247730A3 (en) * | 1986-04-28 | 1989-04-12 | Antibody Technology Limited | Antibodies, their preparation and use and products containing them |
DE3636724A1 (de) * | 1986-10-29 | 1988-06-23 | Joern Dr Med Kekow | Enzymimmunoassay (elisa) zur insulinbestimmung im mikrotiterplattensystem |
US6528292B1 (en) * | 1987-05-29 | 2003-03-04 | Aventis Pharmaceuticals Holdings Inc. | Derivatized polystyrene and other polymer supports for spectroscopic studies |
US5256372A (en) * | 1987-11-06 | 1993-10-26 | Idexx Corporation | Dipstick test device including a removable filter assembly |
US5374524A (en) * | 1988-05-10 | 1994-12-20 | E. I. Du Pont De Nemours And Company | Solution sandwich hybridization, capture and detection of amplified nucleic acids |
US5137804A (en) * | 1988-05-10 | 1992-08-11 | E. I. Du Pont De Nemours And Company | Assay device and immunoassay |
US5614504A (en) * | 1990-08-01 | 1997-03-25 | The University Of South Florida | Method of making inosine monophosphate derivatives and immunopotentiating uses thereof |
US5965379A (en) * | 1991-07-19 | 1999-10-12 | Cytimmune Sciences Inc. | Method for measuring endogenous cytokines |
DE69230000T2 (de) * | 1991-07-19 | 2000-05-11 | Cytimmune Sciences, Inc. | Verfahren und testsatz zur messung von endogenen zytokinen |
US5464749A (en) | 1991-07-22 | 1995-11-07 | Bayer Corporation | Immunoassay of free substances in biological fluids |
US5874423A (en) * | 1992-09-10 | 1999-02-23 | Yissum Research Development Co. Of The Hebrew University Of Jerusalem | Digitalis-like compounds |
US5637467A (en) * | 1992-10-13 | 1997-06-10 | Behringwerke Ag | Heterogeneous assay using a pendulous drop |
AU2635295A (en) * | 1994-06-13 | 1996-01-05 | Henry Ford Health System | A novel neuronal-neonatal gene: neuronatin |
US5843673A (en) * | 1994-10-25 | 1998-12-01 | Curators Of The University Of Missouri | Method of screening for endometriosis |
US6531277B2 (en) | 1994-10-25 | 2003-03-11 | The Curators Of The University Of Missouri | Endometriosis-specific secretory protein |
US20030152909A1 (en) * | 1994-11-16 | 2003-08-14 | Mitrani Eduardo N. | In vitro micro-organs, and uses related thereto |
US5607565A (en) * | 1995-03-27 | 1997-03-04 | Coulter Corporation | Apparatus for measuring analytes in a fluid sample |
US5777093A (en) * | 1995-05-16 | 1998-07-07 | Ramot-University Authority For Applied Research & Industrial Development Ltd. | cDNAs associated with ataxia-telangiectasia |
US5728807A (en) * | 1995-05-16 | 1998-03-17 | Ramot-University Authority For Applied Research And Industrial Development, Ltd. | Mutated proteins associated with ataxia-telangiectasia |
US5858661A (en) | 1995-05-16 | 1999-01-12 | Ramot-University Authority For Applied Research And Industrial Development | Ataxia-telangiectasia gene and its genomic organization |
US6096508A (en) * | 1995-08-16 | 2000-08-01 | Kirkegaard & Perry Laboratoies, Inc. | Method of reducing background in biotin-based assays |
US5840322A (en) * | 1996-12-19 | 1998-11-24 | Ramot-University Authority For Applied Research & Industrial Devel. Ltd. | Anti-oral-microbial adhesion fraction derived from vaccinium |
EP1015471A1 (en) * | 1997-08-21 | 2000-07-05 | Quark Biotech, Inc. | Hypoxia-regulated genes |
US7973156B2 (en) | 1997-08-21 | 2011-07-05 | Quark Pharmaceuticals Inc. | Hypoxia-regulated genes |
US6284496B1 (en) | 1997-10-03 | 2001-09-04 | University Of South Florida | DNA vector for determining the presence of out-of-reading-frame mutations |
EP1027453A4 (en) | 1997-10-17 | 2004-12-01 | Univ South Florida | METHOD FOR DIAGNOSING AND MONITORING CELLULAR IMMUNE DEFICIENCIES |
US7687057B2 (en) | 1998-01-09 | 2010-03-30 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | In vitro micro-organs, and uses related thereto |
US20080206206A1 (en) | 1998-05-07 | 2008-08-28 | University Of South Florida | Bone marrow-derived neuronal cells |
US6344443B1 (en) | 1998-07-08 | 2002-02-05 | University Of South Florida | Peptide antagonists of tumor necrosis factor alpha |
US7605149B1 (en) | 1998-07-13 | 2009-10-20 | University Of South Florida | Modulation of the phospholipase A2 pathway as a therapeutic |
US6187563B1 (en) | 1998-08-07 | 2001-02-13 | Yale University | βIV-spectrin-polypeptides and nucleic acids encoding same |
JP2003523166A (ja) | 1998-09-29 | 2003-08-05 | ガミダ セル リミテッド | 幹細胞および前駆細胞の増殖と分化を制御する方法 |
AU759719B2 (en) * | 1999-02-04 | 2003-04-17 | Pluristem Ltd. | Method and apparatus for maintenance and expansion of hemopoietic stem cells and/or progenitor cells |
US6440682B1 (en) * | 1999-05-28 | 2002-08-27 | Detroit R&D Inc. | Detection of hypertension using immunoreactive metabolic products |
US6787318B1 (en) * | 1999-06-01 | 2004-09-07 | Roskamp Research Institute, Llc | Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology |
US7534605B2 (en) | 1999-06-08 | 2009-05-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases |
US20060127366A1 (en) * | 1999-06-25 | 2006-06-15 | Mitrani Eduardo N | Method and device for inducing biological processes by micro-organs |
CN1420933A (zh) * | 1999-06-25 | 2003-05-28 | 耶路撒冷希伯来大学伊森姆研究发展公司 | 应用微器官诱导血管生成的方法 |
US6875582B1 (en) | 1999-08-19 | 2005-04-05 | Omniscience Pharmaceuticals, Inc. | Methods and targets of antibiotic resistance |
US7811981B2 (en) | 1999-08-30 | 2010-10-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods of and compositions for inhibiting the proliferation of mammalian cells |
US7101839B1 (en) | 1999-08-30 | 2006-09-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods of and compositions for inhibiting the proliferation of mammalian cells |
US6998232B1 (en) | 1999-09-27 | 2006-02-14 | Quark Biotech, Inc. | Methods of diagnosing bladder cancer |
ES2272333T3 (es) | 1999-11-19 | 2007-05-01 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Procedimiento para aumentar el nivel de una sustancia de fermentacion. |
US6544506B2 (en) * | 2000-01-05 | 2003-04-08 | Yeda Research & Development Co. Ltd. | Veto cells effective in preventing graft rejection and devoid of graft versus host potential |
AU2001225441A1 (en) * | 2000-01-24 | 2001-07-31 | Agricultural Research Organization The Volcani Center | Plants tolerant of environmental stress conditions, methods of generating same and novel polynucleotide sequence utilized thereby |
AU785493B2 (en) | 2000-03-27 | 2008-01-03 | Technion Research & Development Foundation Ltd. | Single chain class I major histo-compatibility complexes, constructs encoding same and methods of generating same |
US20040191260A1 (en) * | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
IL135884A (en) * | 2000-04-30 | 2005-08-31 | Yissum Res Dev Co | Method for measuring non-transferrin bound iron |
HUP0300810A2 (hu) | 2000-07-20 | 2003-08-28 | M.G.V.S. Ltd. | Mesterséges értranszplantátum, valamint ennek létrehozása és alkalmazása |
US20040037828A1 (en) | 2002-07-09 | 2004-02-26 | Bar-Ilan University | Methods and pharmaceutical compositions for healing wounds |
PT2078531E (pt) | 2000-08-08 | 2012-08-06 | Technion Res & Dev Foundation | Composições farmacêuticas e métodos úteis para modular a angiogénese |
US20030114410A1 (en) | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
EP1683874A3 (en) | 2000-08-29 | 2006-10-11 | YEDA RESEARCH AND DEVELOPMENT Co. LTD. | Methods of isolating genes encoding proteins of specific function and of screening for pharmaceutically active agents |
WO2002026191A2 (en) * | 2000-09-28 | 2002-04-04 | Nanocyte Inc. | Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue |
US7632522B2 (en) | 2000-09-28 | 2009-12-15 | Nanocyte Inc. | Use of stinging cells/capsules for the delivery of active agents to keratinous substances |
US20070281037A9 (en) * | 2000-09-28 | 2007-12-06 | Nanocyte Inc. | Sterile preparations and compositions including stinging capsules and methods of producing and using same |
US8071740B2 (en) | 2000-11-17 | 2011-12-06 | Vascular Biogenics Ltd. | Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
ES2338529T3 (es) | 2000-11-17 | 2010-05-10 | Vascular Biogenics Ltd. | Prometores que exiben especificidad por celulas endoteliales y metodos para su utilizacion. |
CA2429817C (en) | 2000-11-24 | 2013-02-12 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
US20040052769A1 (en) * | 2000-11-30 | 2004-03-18 | Yair Reisner | Methods of utilizing cultured non-gvhd inducing t lymphocytes to treat disease |
WO2002044736A2 (en) | 2000-11-30 | 2002-06-06 | Molecular Skincare Limited | Diagnosis and treatment of epidermal or skin diseases |
US20020142287A1 (en) * | 2000-12-14 | 2002-10-03 | Hirotaka Yamamoto | High throughput assay to detect inhibitors of the map kinase pathway |
US7087395B1 (en) | 2001-01-16 | 2006-08-08 | Quest Diagnostics Investments Incorporated | Vitamin D assay |
IL157006A0 (en) * | 2001-01-17 | 2004-02-08 | Univ Ramot | Chitinases, derived from carnivorous plants, polynucleotide sequence encoding thereof, and methods of isolating and using same |
CA2475021A1 (en) * | 2001-01-31 | 2002-08-08 | Dror Mevorach | Induction of tolerance by apoptotic and/or necrotic cells |
US20050202098A1 (en) * | 2001-01-31 | 2005-09-15 | Tolaren | Disease therapy using dying or dead cells |
US20030003454A1 (en) | 2001-03-23 | 2003-01-02 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Methods and kits for determining a risk to develop cancer, for evaluating an effectiveness and dosage of cancer therapy and for correlating between an activity of a DNA repair enzyme and a cancer |
US6770622B2 (en) | 2001-06-08 | 2004-08-03 | Gary A. Jarvis | N-terminally truncated galectin-3 for use in treating cancer |
WO2003008534A2 (en) * | 2001-07-19 | 2003-01-30 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Polypeptides having carotenoids isomerase catalytic activity, nucleic acids encoding same and uses thereof |
CA2458640A1 (en) | 2001-08-16 | 2003-03-06 | Bar-Ilan University | Diagnosis, prevention and treatment of cancer |
US7138144B2 (en) * | 2001-09-07 | 2006-11-21 | Nadir Askenasy | Method of inducing immune tolerance via blood/lymph flow-restricted bone marrow transplantation |
US20040136972A1 (en) | 2001-09-07 | 2004-07-15 | Yeda Research And Development Co. Ltd. | Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues |
EP1436313B1 (en) | 2001-10-19 | 2010-09-22 | Vascular Biogenics Ltd. | Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy |
AUPR842501A0 (en) * | 2001-10-23 | 2001-11-15 | Epipop Pty Ltd | A method for identification and development of therapeutic agents |
WO2003048298A2 (en) * | 2001-12-05 | 2003-06-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Nanoparticles containing polymeric nucleic acid homologs, pharmaceutical compositions and articles of manufacture containing same and methods of use thereof |
US20050085432A1 (en) * | 2001-12-26 | 2005-04-21 | Aviva Lapidot | Methods of using conjugates of saccharides and acetamidino or guanidino compounds for treating bacterial infections |
IL152904A0 (en) | 2002-01-24 | 2003-06-24 | Gamida Cell Ltd | Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations |
EP1465982A4 (en) | 2002-01-25 | 2006-06-07 | Gamida Cell Ltd | PROCESS FOR EXPANSION OF STEM AND PRESERVATIVE CELLS AND EXPANDED CELL POPULATIONS THEREWITH OBTAINED |
US7781396B2 (en) * | 2002-01-31 | 2010-08-24 | Tel Aviv University Future Technology Development L.P. | Peptides directed for diagnosis and treatment of amyloid-associated disease |
US20040052928A1 (en) * | 2002-09-06 | 2004-03-18 | Ehud Gazit | Peptides and methods using same for diagnosing and treating amyloid-associated diseases |
US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
CA2476625A1 (en) * | 2002-02-20 | 2003-08-28 | Dyax Corp. | Mhc-peptide complex binding ligands |
WO2003078567A2 (en) * | 2002-03-18 | 2003-09-25 | Gamida-Cell Ltd. | Methods of inducing differentiation in ex vivo expanded stem cells |
IL164191A0 (en) * | 2002-03-26 | 2005-12-18 | Nanocyte Inc | Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosme tic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue nanocyte inc. |
US20040121442A1 (en) * | 2002-05-05 | 2004-06-24 | Ilan Chet | Fungal chitinase, polynucleotide sequences encoding same, promoters of same, and uses thereof |
EP2561889A3 (en) | 2002-08-01 | 2013-04-03 | Yeda Research and Development Co. Ltd. | Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels |
US7267981B2 (en) | 2002-10-07 | 2007-09-11 | Technion Research & Development Foundation Ltd. | Human foreskin fibroblasts for culturing ES cells |
AU2003284968A1 (en) * | 2002-10-25 | 2004-05-13 | University Of South Florida | Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease |
EP2295980A1 (en) | 2002-10-30 | 2011-03-16 | Yissum Research Development Company, of The Hebrew University of Jerusalem | Molecules and methods using same for measuring non-transferrin bound iron |
US20050054097A1 (en) * | 2002-11-17 | 2005-03-10 | Tony Peled | EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures |
WO2004050826A2 (en) * | 2002-11-29 | 2004-06-17 | Technion Research & Development Foundation Ltd. | Method of dynamically culturing embryonic stem cells |
US7491699B2 (en) * | 2002-12-09 | 2009-02-17 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures and methods of generating and using the same |
DE60334846D1 (de) | 2002-12-12 | 2010-12-16 | R B T Rakuto Bio Technologies | VERWENDUNG von LIGNINPEROXIDASE ZUR HAUT- UND HAARAUFHELLUNG |
DK1572984T3 (da) | 2002-12-16 | 2016-06-13 | Technion Res & Dev Foundation | Feedercellefrit, xenofrit dyrkningssystem til humane embryonale stamceller |
AU2003288700B2 (en) | 2003-01-02 | 2009-11-19 | Rappaport Family Institute For Research In The Medical Sciences | Methods of predicting a benefit of antioxidant therapy for prevention of cardiovascular disease in hyperglycemic patients |
ATE426575T1 (de) | 2003-01-07 | 2009-04-15 | Univ Ramot | Peptidenanostrukturen die fremdmaterial enthalten,und verfahren zur herstellung derselben |
US7786071B2 (en) | 2003-03-04 | 2010-08-31 | Yeda Research And Development Co. Ltd. | Pon polypeptides polynucleotides encoding same and compositions and methods utilizing same |
US20050054103A1 (en) * | 2003-03-07 | 2005-03-10 | Tony Peled | Expansion of renewable stem cell populations using modulators of PI 3-kinase |
US8017113B2 (en) | 2003-03-12 | 2011-09-13 | Rappaport Family Institute For Research In The Medical Sciences | Compositions and methods for diagnosing and treating an inflammation |
US7294701B2 (en) * | 2003-04-02 | 2007-11-13 | Technion Research & Development Foundation Ltd. | Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same |
EP2330132B1 (en) | 2003-04-04 | 2013-08-14 | Yeda Research and Development Co. Ltd. | Antibodies against MMP2 or MMP9 and pharmaceutical compositions containing same useful for inhibiting activity of said metalloproteins |
EP1611233B1 (en) | 2003-04-08 | 2016-01-06 | Yeda Research And Development Co., Ltd. | Stem cells having increased sensitivity to sdf-1 and methods of generating and using same |
FR2853551B1 (fr) | 2003-04-09 | 2006-08-04 | Lab Francais Du Fractionnement | Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee |
US7321065B2 (en) * | 2003-04-18 | 2008-01-22 | The Regents Of The University Of California | Thyronamine derivatives and analogs and methods of use thereof |
BR122016024209B1 (pt) | 2003-05-22 | 2019-08-20 | Evogene Ltd. | Método para aumentar a biomassa e/ou tolerância de uma planta ao estresse salino e construto de ácido nucleico |
AU2005234725B2 (en) | 2003-05-22 | 2012-02-23 | Evogene Ltd. | Methods of Increasing Abiotic Stress Tolerance and/or Biomass in Plants and Plants Generated Thereby |
US7554007B2 (en) | 2003-05-22 | 2009-06-30 | Evogene Ltd. | Methods of increasing abiotic stress tolerance and/or biomass in plants |
US20050020499A1 (en) * | 2003-05-27 | 2005-01-27 | Bar Ilan University | Methods of attenuating cocaine seeking behavior employing glial cell-derived neurotrophic factor (GDNF) and pharmaceutical compositions and articles of manufacture suited for use in practice of the method |
US8129514B2 (en) * | 2003-06-19 | 2012-03-06 | Evogene Ltd. | Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same |
EP1636333A4 (en) * | 2003-06-19 | 2007-10-24 | Evogene Ltd | NUCLEOTIDE SEQUENCES FOR REGULATING GENE EXPRESSION IN VEGETABLE TRICHROMES, AND HYBRID GENES AND METHODS IN WHICH THEY INTERVENE |
KR101215821B1 (ko) | 2003-06-30 | 2012-12-28 | 텔 아비브 유니버시티 퓨쳐 테크놀로지 디벨롭먼트 엘.피. | 아밀로이드 관련 질환을 진단 및 처치하기 위한 펩타이드, 그것에 대한 항체, 및 그 사용방법 |
EP1654348A4 (en) * | 2003-08-14 | 2008-02-13 | Bio Balance Corp | BACTERIAL STRAINS, COMPOSITIONS AND PROBIOTIC USE THEREOF |
US7625707B2 (en) | 2003-10-02 | 2009-12-01 | Ramot At Tel Aviv University Ltd. | Antibacterial agents and methods of identifying and utilizing same |
DK1678209T3 (da) | 2003-10-07 | 2011-06-27 | Yeda Res & Dev | Antistoffer mod nik, deres frembringelse samt anvendelse |
IL158287A0 (en) | 2003-10-07 | 2004-05-12 | Yeda Res & Dev | Antibodies to nik, their preparation and use |
CA2542221A1 (en) * | 2003-10-23 | 2005-05-06 | Pfizer Products Inc. | Vaccine for periodontal disease |
CA2547459C (en) | 2003-11-30 | 2013-10-08 | Yeda Research And Development Co. Ltd | Modulators of nik-siva complex formation for treating immune disorders |
WO2005059100A2 (en) * | 2003-12-12 | 2005-06-30 | New York University | Methods and compositions relating to cystatin c |
US20100221233A1 (en) * | 2003-12-15 | 2010-09-02 | University Of South Florida | Compositions and methods for enhancing neuroprotection via administration of stem cells and blood brain barrier permeabilizers |
WO2005061018A1 (en) | 2003-12-22 | 2005-07-07 | Regentis Biomaterials Ltd. | Matrix comprising naturally-occurring protein backbone |
US8007847B2 (en) | 2004-01-13 | 2011-08-30 | Eytan Biderman | Feeding formula appliance |
US7423139B2 (en) * | 2004-01-20 | 2008-09-09 | Insight Biopharmaceuticals Ltd. | High level expression of recombinant human erythropoietin having a modified 5′-UTR |
EP1713900A4 (en) * | 2004-01-27 | 2009-06-17 | Compugen Ltd | METHOD AND SYSTEMS FOR COMMENTING BIOMOLECULAR SEQUENCES |
EP3006039B1 (en) | 2004-03-02 | 2021-01-06 | Acceleron Pharma Inc. | Alk7 polypeptides for use in promoting fat loss |
US8352031B2 (en) | 2004-03-10 | 2013-01-08 | Impulse Dynamics Nv | Protein activity modification |
CN101948846A (zh) | 2004-06-14 | 2011-01-19 | 伊沃基因有限公司 | 参与植物纤维发育的多核苷酸和多肽和使用它们的方法 |
US8680062B2 (en) * | 2004-07-06 | 2014-03-25 | Deliversir Ltd. | System for delivering therapeutic agents into living cells and cells nuclei |
US20090156471A1 (en) * | 2004-07-15 | 2009-06-18 | Ramot At Tel Aviv University Ltd. | Use of anti-amyloid agents for treating and typing pathogen infections |
WO2006030442A2 (en) | 2004-09-16 | 2006-03-23 | Gamida-Cell Ltd. | Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells |
US8000900B2 (en) | 2004-09-21 | 2011-08-16 | Microsoft Corporation | Association-based predictions of pathogen characteristics |
US20060095241A1 (en) * | 2004-10-29 | 2006-05-04 | Microsoft Corporation | Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails |
EP1809751B1 (en) | 2004-09-29 | 2010-09-01 | CollPlant Ltd. | Collagen producing plants and methods of generating and using same |
ES2524601T3 (es) * | 2004-09-29 | 2014-12-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | RNasa T2 humana recombinante y usos de la misma |
WO2006040765A1 (en) * | 2004-10-12 | 2006-04-20 | Closed Loop Therapies Ltd. | Methods and implantable devices for treating supraventricular arrhythmias |
US8478535B2 (en) | 2004-10-29 | 2013-07-02 | Microsoft Corporation | Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails |
US20060134680A1 (en) * | 2004-12-22 | 2006-06-22 | Alexander Kotlyar | Homogeneous populations of nucleic acids, methods of synthesyzing same and uses thereof |
EP1844403A4 (en) | 2005-01-16 | 2010-06-23 | Zlango Ltd | SIGNS COMMUNICATION |
WO2006075335A2 (en) * | 2005-01-16 | 2006-07-20 | Zlango Ltd. | Communications network system and methods for using same |
US8019818B2 (en) * | 2005-01-18 | 2011-09-13 | Zlango Ltd. | Communications network system and methods for using same |
EP1843850B1 (en) | 2005-01-31 | 2015-11-18 | Realbio Technologies Ltd. | Multistep reaction lateral flow capillary device |
ES2366654T3 (es) | 2005-02-17 | 2011-10-24 | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT CO., LTD. | Biofosfonatos para tratar la endometriosis. |
JP5432455B2 (ja) | 2005-02-25 | 2014-03-05 | ザ ステート オブ イスラエル、ミニストリー オブ アグリカルチャー アンド ルーラル ディベロップメント、アグリカルチュラル リサーチ オーガナイゼイション、(エー.アール.オー.)、ボルカニ センター | 炎症治療用の果実細胞培養抽出物 |
US7695927B2 (en) * | 2005-03-18 | 2010-04-13 | Detroit R & D | Detection of hypertension using glucuronidated metabolic products |
US20090068207A1 (en) * | 2005-04-15 | 2009-03-12 | Vascular Biogenics Ltd. | Compositions Containing Beta 2-Glycoprotein I-Derived Peptides for the Prevention and/or Treatment of Vascular Disease |
US8834862B2 (en) * | 2005-04-19 | 2014-09-16 | Nanocyte Inc. | Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent |
WO2006116742A2 (en) * | 2005-04-28 | 2006-11-02 | Ventana Medical Systems, Inc. | Fluorescent nanoparticles conjugated to antibodies via a peg linker |
JP5628476B2 (ja) | 2005-04-28 | 2014-11-19 | ベンタナ・メデイカル・システムズ・インコーポレーテツド | 抗体コンジュゲート |
WO2006126208A2 (en) | 2005-05-26 | 2006-11-30 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions and methods using same for delivering agents into a target organ protected by a blood barrier |
EP2465924A3 (en) | 2005-06-16 | 2013-01-02 | Ramot at Tel-Aviv University Ltd. | Isolated cells and populations comprising same for the treament of cns diseases |
US20070225242A1 (en) * | 2005-06-21 | 2007-09-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method and composition for treating and preventing tumor metastasis in vivo |
EP2487182B1 (en) | 2005-07-07 | 2019-10-23 | FULCRUM SP Ltd. | Sp1 polypeptides, modified sp1 polypeptides and uses thereof |
CA2614531C (en) | 2005-07-07 | 2015-06-16 | Avraham Hochberg | Nucleic acid agents for downregulating h19, and methods of using same |
WO2007010533A2 (en) | 2005-07-18 | 2007-01-25 | Protalix Ltd. | Mucosal or enteral administration of biologically active macromolecules |
US7993657B2 (en) | 2005-07-26 | 2011-08-09 | University Of Medicine And Dentistry Of New Jersey | Antibody profiles characteristic of tuberculosis state |
US8642330B2 (en) * | 2005-08-08 | 2014-02-04 | Onconon, Llc | Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility |
EP1928479B1 (en) | 2005-08-24 | 2016-06-08 | Yeda Research And Development Co., Ltd. | Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance |
AU2006286149B2 (en) | 2005-08-29 | 2012-09-13 | Technion Research And Development Foundation Ltd. | Media for culturing stem cells |
JP2009508516A (ja) * | 2005-09-22 | 2009-03-05 | イッサム リサーチ ディベロプメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム | 核酸構築物、薬剤組成物、及び癌治療のためのその使用方法 |
US20070087437A1 (en) * | 2005-10-14 | 2007-04-19 | Jifan Hu | Methods for rejuvenating cells in vitro and in vivo |
MX350551B (es) | 2005-10-24 | 2017-09-08 | Evogene Ltd | Polipeptidos aislados, polinucleotidos que los codifican, plantas transgenicas que expresan los mismos y metodos para usarlos. |
JP4888387B2 (ja) * | 2005-11-18 | 2012-02-29 | 三菱電機株式会社 | エレベータのかご照明装置 |
JP5199880B2 (ja) * | 2005-11-23 | 2013-05-15 | ベンタナ・メデイカル・システムズ・インコーポレーテツド | 分子コンジュゲート |
CA2632288A1 (en) | 2005-11-29 | 2007-06-07 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
US8846393B2 (en) | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
EP2237037A1 (en) | 2005-12-12 | 2010-10-06 | Gyros Patent Ab | Microfluidic device and use thereof |
US20070134739A1 (en) * | 2005-12-12 | 2007-06-14 | Gyros Patent Ab | Microfluidic assays and microfluidic devices |
WO2007080559A2 (en) | 2006-01-16 | 2007-07-19 | Zlango Ltd. | Iconic communication |
US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US8476234B2 (en) | 2006-02-03 | 2013-07-02 | Prolor Biotech Inc. | Long-acting coagulation factors and methods of producing same |
US9458444B2 (en) | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
WO2007092252A2 (en) | 2006-02-03 | 2007-08-16 | Modigene Inc | Long-acting polypeptides and methods of producing same |
US8048848B2 (en) | 2006-02-03 | 2011-11-01 | Prolor Biotech Ltd. | Long-acting interferons and derivatives thereof and methods thereof |
US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
US8759292B2 (en) | 2006-02-03 | 2014-06-24 | Prolor Biotech, Llc | Long-acting coagulation factors and methods of producing same |
BRPI0706967A2 (pt) | 2006-02-06 | 2011-04-12 | Rappaport Family Inst For Res | método e kit para diagnosticar dmt1 |
AU2007224386B2 (en) | 2006-03-06 | 2013-12-19 | Zetiq Technologies Ltd. | Methods and compositions for identifying a cell phenotype |
EP2366775B1 (en) | 2006-03-23 | 2015-04-22 | Pluristem Ltd. | Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy |
EP2004858A4 (en) | 2006-03-28 | 2009-12-09 | Tel Hashomer Medical Res Infrastructure & Services Ltd | METHOD AND KITS FOR DETERMINING AN INVESTMENT TO WARFARINE RESISTANCE |
US8071323B2 (en) * | 2006-04-07 | 2011-12-06 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Human monoclonal antibodies that bind human insulin like growth factors and their use |
ES2549128T3 (es) * | 2006-05-19 | 2015-10-23 | Technion Research And Development Foundation Ltd. | Proteínas de fusión, usos de las mismas y procesos para producir las mismas |
US20070281883A1 (en) * | 2006-06-05 | 2007-12-06 | Hanna Rosenfeld | Development of follicle stimulating hormone agonists and antagonists in fish |
US8629259B2 (en) | 2006-07-20 | 2014-01-14 | Yeda Research And Development Co. Ltd. | Photosynthetic organisms and compositions and methods of generating same |
EP2064319B1 (en) | 2006-08-28 | 2017-02-22 | Yeda Research and Development Co. Ltd. | Methods of generating glial and neuronal cells and use of same for the treatment of medical conditions of the cns |
US7888059B2 (en) * | 2006-10-05 | 2011-02-15 | Yeda Research And Development Co. Ltd. | Highly purified and stabilized Na,K-ATPase isoforms and methods of producing same |
WO2008041183A2 (en) | 2006-10-05 | 2008-04-10 | Technion Research & Development Foundation Ltd. | Microtubes and methods of producing same |
MX349479B (es) * | 2006-12-20 | 2017-07-31 | Evogene Ltd | Polinucleotidos y polipeptidos involucrados en el desarrollo de fibra vegetal y metodos de uso. |
EP2111449B1 (en) * | 2007-01-16 | 2012-03-07 | Yissum Research Development Company of the Hebrew University of Jerusalem | H19 silencing nucleic acid agents for treating rheumatoid arthritis |
WO2008093331A1 (en) * | 2007-01-29 | 2008-08-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Antibody conjugates for circumventing multi-drug resistance |
US8911996B2 (en) | 2007-01-31 | 2014-12-16 | Technion Research & Development Foundation Limited | Electrospun scaffolds and methods of generating and using same |
EP2125050B1 (en) | 2007-02-01 | 2014-07-30 | Technion Research & Development Foundation Ltd. | Albumin fibers and fabrics and methods of generating and using same |
WO2008104979A2 (en) | 2007-02-28 | 2008-09-04 | Yeda Research And Development Co. Ltd. | Nuclear targeting sequences |
CA2682093A1 (en) | 2007-03-29 | 2008-10-09 | Technion Research & Development Foundation Ltd. | Antibodies, methods and kits for diagnosing and treating melanoma |
JP2010523104A (ja) | 2007-04-02 | 2010-07-15 | ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド | ガン細胞検出方法ならびにガン疾患の診断およびガン疾患の処置のモニタリングのためのその使用 |
MX2009010858A (es) | 2007-04-09 | 2009-11-02 | Evogene Ltd | Polinucleotidos, polipeptidos y metodos para aumentar el contenido de aceite, la velocidad de crecimiento y biomasa de las plantas. |
WO2014064687A1 (en) | 2012-10-22 | 2014-05-01 | Deliversir Ltd | A system for delivering therapeutic agents into living cells and cells nuclei |
US9156865B2 (en) | 2007-04-23 | 2015-10-13 | Deliversir Ltd | System for delivering therapeutic agents into living cells and cells nuclei |
EP2144633B1 (en) * | 2007-04-23 | 2014-07-16 | Deliversir Ltd | A system for delivering therapeutic agents into living cells and cells nuclei |
US9556210B2 (en) | 2007-04-23 | 2017-01-31 | Sabag-Rfa Ltd. | System for delivering therapeutic agents into living cells and cells nuclei |
EP2152905B1 (en) | 2007-05-01 | 2015-12-02 | Tel Hashomer Medical Research Infrastructure and Services Ltd. | Methods and kits for detecting fetal cells in the maternal blood |
CA2685954A1 (en) | 2007-05-03 | 2008-11-13 | Agency For Science, Technology And Research | Antibodies binding to an intracellular prl-1 or prl-3 polypeptide |
CA2685701C (en) | 2007-05-07 | 2019-01-15 | Protalix Ltd. | Large scale disposable bioreactor |
ATE540115T1 (de) | 2007-07-11 | 2012-01-15 | Yeda Res & Dev | Nukleinsäurekonstruktsysteme mit fähigkeit zur diagnose oder behandlung eines zellzustands |
IL184627A0 (en) | 2007-07-15 | 2008-12-29 | Technion Res & Dev Foundation | Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue |
JP2010533705A (ja) | 2007-07-15 | 2010-10-28 | ヒルマン,イチャク | 抗菌ペプチドまたはその阻害剤を用いた疾病治療 |
BR122020022203B1 (pt) | 2007-07-24 | 2021-04-20 | Evogene Ltd | método de aumento da taxa de crescimento de uma planta |
SI2185198T1 (sl) | 2007-08-02 | 2015-04-30 | Gilead Biologics, Inc. | Inhibitorji LOX in LOXL2 ter njihova uporaba |
BRPI0814479A2 (pt) | 2007-08-15 | 2016-07-12 | Yeda Res & Dev | "método para regular uma atividade de metaloproteinase 9 (mm9), método para identificar um agente capaz de regular especificamente a mmp-9, método de tratar a afecção clínica mediada pela mmp-9, molécula capaz de regular especificamente uma atividade da mmp-9, anticorpo humanizado e composição farmacêutica" |
AU2008299318A1 (en) | 2007-09-12 | 2009-03-19 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | Methods of treating tumors in immune-privileged sites |
BRPI0815946B8 (pt) | 2007-09-19 | 2021-05-25 | Pluristem Ltd | artigo de fabricação |
ES2620487T3 (es) | 2007-10-19 | 2017-06-28 | Rappaport Family Institute For Research In The Medical Sciences | Composiciones que comprenden semaforinas para uso en el tratamiento del cáncer |
EP2599790A1 (en) | 2007-11-26 | 2013-06-05 | Yissum Research Development Company of The Hebrew University of Jerusalem | Compositions comprising fibrous polypeptides and polysachharides |
CN101977928B (zh) | 2007-12-27 | 2014-12-10 | 伊沃基因有限公司 | 用于改进植物的水分利用效率、肥料利用效率、生物/非生物胁迫耐受性、产量和生物量的分离多肽、多核苷酸 |
EP2245055A2 (en) * | 2008-01-31 | 2010-11-03 | Compugen Ltd. | Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
US9297094B2 (en) | 2008-02-21 | 2016-03-29 | Technion Research & Development Foundation Ltd. | Use of electrospun microtubes for drug delivery |
US20110033473A1 (en) * | 2008-04-09 | 2011-02-10 | Yoram Reiter | Anti influenza antibodies and uses thereof |
US8747855B2 (en) * | 2008-04-09 | 2014-06-10 | Technion Research & Development Foundation Limited | Anti human immunodeficiency antibodies and uses thereof |
CN102083615B (zh) * | 2008-04-10 | 2014-08-13 | 战略系统有限公司 | 用于三维模型打印的系统和方法 |
CN104491845A (zh) | 2008-04-18 | 2015-04-08 | 科尔普兰特有限公司 | 产生和使用原胶原的方法 |
MX2010011511A (es) | 2008-04-21 | 2011-06-09 | Danziger Innovations Ltd | Vectores de expresion viral de planta y uso de los mismos para generar variaciones genotipicas en genomas de plantas. |
SG176464A1 (en) | 2008-05-09 | 2011-12-29 | Agency Science Tech & Res | Diagnosis and treatment of kawasaki disease |
CA3148194A1 (en) | 2008-05-22 | 2009-11-26 | Evogene Ltd. | Isolated polynucleotides and peptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency |
US9393273B2 (en) | 2008-05-27 | 2016-07-19 | Pluristem Ltd. | Methods of treating inflammatory colon diseases |
EP3514229A1 (en) | 2008-05-28 | 2019-07-24 | Ramot at Tel-Aviv University Ltd. | Mesenchymal stem cells for the treatment of cns diseases |
CN102076415B (zh) | 2008-06-29 | 2015-06-24 | 瑞尔比奥技术有限公司 | 尤其可用作生物测定过程中的捕捉装置的液体转移装置 |
JP5756014B2 (ja) | 2008-08-08 | 2015-07-29 | エイジェンシー・フォー・サイエンス,テクノロジー・アンド・リサーチ(エイ・スター) | がんの診断および治療のためのvhz |
WO2010017544A2 (en) | 2008-08-08 | 2010-02-11 | Genisphere, Inc. | Long-acting dna dendrimers and methods thereof |
BRPI0912898B1 (pt) | 2008-08-18 | 2022-04-12 | Evogene Ltd | Método para aumentar a eficiência de uso do nitrogênio e/ou tolerância à deficiência de nitrogênio de uma planta |
CN105708862B (zh) | 2008-09-02 | 2020-11-06 | 普拉里斯坦有限公司 | 来自胎盘组织的粘附细胞及其在治疗中的用途 |
US8367392B2 (en) * | 2008-09-05 | 2013-02-05 | Transalgae Ltd. | Genetic transformation of algal and cyanobacteria cells by microporation |
US20110305682A1 (en) | 2008-09-11 | 2011-12-15 | Ben Gurion University Of The Negev Research And Development Authority | Compositions and Methods for Treating S. Pneumonia Infection |
CN107595889A (zh) | 2008-09-12 | 2018-01-19 | 克里奥普拉斯低温生物有限公司 | 缺血性组织的细胞疗法 |
JP5676451B2 (ja) | 2008-09-24 | 2015-02-25 | テル ハショメール メディカル リサーチ,インフラストラクチャ アンド サービシーズ リミテッド | ペプチド |
EP2342356A4 (en) | 2008-09-29 | 2012-11-21 | Univ Ben Gurion | AMYLOID BETA PEPTIDASES AND METHOD OF USE THEREOF |
EP2347014B1 (en) | 2008-10-30 | 2016-09-21 | Evogene Ltd. | Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficieny |
US20110229892A1 (en) | 2008-11-17 | 2011-09-22 | Yehuda G Assaraf | Method for predicting a patient's responsiveness to anti-folate therapy |
WO2010058396A1 (en) | 2008-11-19 | 2010-05-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | A cd44vra antibody and diagnostic and therapeutic methods using same |
WO2010061383A1 (en) | 2008-11-26 | 2010-06-03 | Biodalia Microbiological Technologies Ltd. | A method of in-situ enrichment of foods with fructan |
WO2010064231A1 (en) | 2008-12-02 | 2010-06-10 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Methods of analyzing a-i rna editing and nucleic acid constructs capable of same |
WO2010064247A1 (en) | 2008-12-03 | 2010-06-10 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Methods and kits for determining predisposition to cancer |
US8734759B2 (en) | 2008-12-05 | 2014-05-27 | Yeda Research And Development Co. Ltd. | Methods of diagnosing and treating motor neuron diseases |
WO2010071610A1 (en) | 2008-12-19 | 2010-06-24 | Agency For Science, Technology And Research (A*Star) | Severe chikungunya biomarkers |
EP2376653A2 (en) | 2008-12-29 | 2011-10-19 | Yissum Research Development Company of The Hebrew University of Jerusalem | Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection |
MX340023B (es) | 2008-12-29 | 2016-06-22 | Evogene Ltd | Polinucleotidos, polipeptidos codificados, y metodos para utilizarlos para aumentar la tolerancia al estres abiotico, biomasa y/o rendimiento en plantas que los expresan. |
SG10201504379VA (en) | 2008-12-29 | 2015-07-30 | Tel Hashomer Medical Res Infrastructure & Services Ltd | Peptides and compositions for prevention of cell adhesion and methods of using same |
WO2010076794A1 (en) | 2008-12-31 | 2010-07-08 | Technion Research & Development Foundation Ltd. | Method of denitrifying brine and systems capable of same |
WO2010080769A2 (en) | 2009-01-06 | 2010-07-15 | Arresto Biosciences, Inc. | Chemotherapeutic methods and compositions |
IL196820A0 (en) | 2009-02-01 | 2009-11-18 | Yissum Res Dev Co | Devitalized, acellular scaffold matrices derived from micro-organs seeded with various cells |
EP2391377A2 (en) | 2009-02-02 | 2011-12-07 | Ramot at Tel-Aviv University Ltd. | Peptides, pharmaceutical compositions comprising same and uses thereof |
WO2010089707A1 (en) | 2009-02-04 | 2010-08-12 | Yeda Research And Development Co. Ltd. | Methods and kits for determining sensitivity or resistance of prostate cancer to radiation therapy |
EP2401362B1 (en) | 2009-02-26 | 2017-04-12 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Isolated populations of renal stem cells and methods of isolating and using same |
CA3123543A1 (en) | 2009-03-02 | 2010-09-10 | Evogene Ltd. | Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics |
PL2406279T3 (pl) | 2009-03-09 | 2016-07-29 | Univ Ramot | Kompozycje do zapobiegania i leczenia chorób neurodegeneratywnych. |
WO2010103517A1 (en) | 2009-03-12 | 2010-09-16 | Rappaport Family Institute For Research In The Medical Sciences | Soluble compositions for the treatment of cxcr3-ligand associated diseases |
WO2010113096A1 (en) | 2009-03-30 | 2010-10-07 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Methods of predicting clinical course and treating multiple sclerosis |
EP2344179A1 (en) | 2009-04-01 | 2011-07-20 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | A method of regulating proliferation and differentiation of keratinocyes |
WO2010116375A1 (en) | 2009-04-08 | 2010-10-14 | Yeda Research And Development Co. Ltd. | Isolated peptides for regulating apoptosis |
DK2424896T3 (da) | 2009-04-30 | 2015-12-14 | Tel Hashomer Medical Res Infrastructure & Services Ltd | Anti-CEACAM1-antistoffer og fremgangsmåder til anvendelse deraf |
WO2010134073A1 (en) | 2009-05-19 | 2010-11-25 | Zetiq Technologies Ltd. | Kits for and methods of differential staining of cervical cancer cells and/or tissues |
WO2010137013A1 (en) | 2009-05-27 | 2010-12-02 | Ramot At Tel Aviv University Ltd. | Crystallized photosystem i units from the pea plant and their use in solid state devices |
US20120078163A1 (en) | 2009-05-27 | 2012-03-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of generating connective tissue |
WO2010137017A2 (en) | 2009-05-27 | 2010-12-02 | Yeda Research And Development Co. Ltd. | Proteasome inhibitors and uses thereof |
EP2435078A1 (en) | 2009-05-28 | 2012-04-04 | Yeda Research and Development Co. Ltd. | Methods of treating inflammation |
EP2440033B1 (en) | 2009-06-10 | 2017-03-15 | Evogene Ltd. | Isolated polynucleotides and polypeptides, and methods of using same for increasing nitrogen use efficiency, yield, growth rate, vigor, biomass, oil content, and/or abiotic stress tolerance |
IN2012DN00715A (da) | 2009-06-24 | 2015-06-19 | Health Corp Rambam | |
US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
WO2011004379A1 (en) | 2009-07-10 | 2011-01-13 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Compositions and methods for treating cancer |
CA2768725A1 (en) | 2009-07-21 | 2011-01-27 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | A method of diagnosing cancer |
GB0913442D0 (en) | 2009-07-31 | 2009-09-16 | Univ Ramot | Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof |
WO2011021194A2 (en) | 2009-08-17 | 2011-02-24 | Technion Research & Development Foundation Ltd. | Pericyte progenitor cells and methods of generating and using same |
AU2010284000A1 (en) * | 2009-08-21 | 2012-03-22 | Gilead Biologics, Inc. | In vitro screening assays |
US20120157512A1 (en) | 2009-08-21 | 2012-06-21 | Monsanto Technology Llc | Preventing and Curing Beneficial Insect Diseases Via Plant Transcribed Molecules |
SG2014004816A (en) | 2009-08-21 | 2014-03-28 | Gilead Biologics Inc | Catalytic domains from lysyl oxidase and loxl2 |
CN106619515A (zh) | 2009-08-27 | 2017-05-10 | 工业研究与发展基金会有限公司 | 脂质体组合物及其用途 |
US9610331B2 (en) | 2009-09-08 | 2017-04-04 | Yeda Research And Development Co. Ltd. | Methods for hematopoietic precursor mobilization |
EP2475784A1 (en) | 2009-09-08 | 2012-07-18 | Ramot at Tel-Aviv University Ltd. | Methods of diagnosing amyotrophic lateral sclerosis (als) |
US20120171213A1 (en) | 2009-09-10 | 2012-07-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of treating tumors |
US8212001B2 (en) | 2009-09-17 | 2012-07-03 | Ramot At Tel-Aviv University Ltd. | Peptides for the treatment of oxidative stress related disorders |
US8735124B2 (en) | 2009-09-17 | 2014-05-27 | Yeda Research And Development Co. Ltd. | Isolated PON1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage |
WO2011033506A2 (en) | 2009-09-17 | 2011-03-24 | Yeda Research And Development Co. Ltd. | Isolated pon1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage |
US20110081706A1 (en) * | 2009-10-02 | 2011-04-07 | TransAlgae Ltd | Method and system for efficient harvesting of microalgae and cyanobacteria |
US8962584B2 (en) | 2009-10-14 | 2015-02-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Compositions for controlling Varroa mites in bees |
CA2777448C (en) | 2009-10-14 | 2023-02-28 | Ilan Sela | Compositions for controlling varroa mites in bees |
EP2488209B1 (en) | 2009-10-16 | 2016-09-28 | Rutgers, the State University of New Jersey | Method for treating chronic nerve tissue injury using a cell therapy strategy |
WO2011048600A1 (en) | 2009-10-21 | 2011-04-28 | Danziger Innovations Ltd. | Generating genotypic variations in plant genomes by gamete infection |
IL201999A (en) | 2009-11-08 | 2017-10-31 | Medical Res & Development Fund For Health Services Bnai Zion Medical Center The State Of Israel | A knockout mouse of the 1 – mo gene, a gene associated with morbidly extreme obesity |
WO2011058555A1 (en) | 2009-11-12 | 2011-05-19 | Yeda Research And Development Co. Ltd. | A method of editing dna in a cell and constructs capable of same |
CA3174901A1 (en) | 2009-11-12 | 2011-05-19 | Technion Research & Development Foundation Ltd. | Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state |
EP2498806B1 (en) | 2009-11-12 | 2014-12-31 | Ramot at Tel-Aviv University Ltd. | Compositions comprising pedf and uses of same in the treatment and prevention of ovary-related syndromes |
US20120230974A1 (en) | 2009-11-17 | 2012-09-13 | Protalix Ltd | Alkaline alpha galactosidase for the treatment of fabry disease |
EP2504472A1 (en) | 2009-11-24 | 2012-10-03 | Collplant Ltd. | Method of generating collagen fibers |
AU2010322808B9 (en) | 2009-11-30 | 2014-08-07 | Pluri Biotech Ltd | Adherent cells from placenta and use of same in disease treatment |
WO2011067745A2 (en) | 2009-12-06 | 2011-06-09 | Rosetta Green Ltd. | Compositions and methods for enhancing plants resistance to abiotic stress |
US8778904B2 (en) | 2009-12-09 | 2014-07-15 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the CNS |
EP2519097B1 (en) | 2009-12-28 | 2016-03-02 | Evogene Ltd. | Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency |
DK3184109T3 (da) | 2009-12-29 | 2021-02-15 | Gamida Cell Ltd | Fremgangsmåder til forbedring af natural killer-cellers proliferation og aktivitet |
AU2011204405B2 (en) | 2010-01-05 | 2015-06-18 | Vascular Biogenics Ltd. | Methods for use of a specific anti-angiogenic adenoviral agent |
WO2011086509A1 (en) | 2010-01-12 | 2011-07-21 | Vascular Biogenics Ltd. | Methods of producing adenovirus vectors and viral preparations generated thereby |
CN102822202B (zh) | 2010-01-27 | 2015-07-22 | 耶达研究及发展有限公司 | 抑制金属蛋白的抗体 |
CA2789022A1 (en) | 2010-02-04 | 2011-08-11 | Gilead Biologics, Inc. | Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor |
WO2011099006A2 (en) | 2010-02-11 | 2011-08-18 | Yeda Research And Development Co. Ltd. | Enzymatic systems for carbon fixation and methods of generating same |
WO2011104708A2 (en) | 2010-02-24 | 2011-09-01 | Ben Gurion University Of The Negev Research And Development Authority | Methods for inhibiting necrosis |
WO2011107939A1 (en) | 2010-03-01 | 2011-09-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of predicting efficacy of an anti-vegfa treatment for solid tumors |
WO2011107994A1 (en) | 2010-03-04 | 2011-09-09 | Yeda Research And Development Co. Ltd. | Methods of measuring protein stability |
EP2545176B1 (en) | 2010-03-08 | 2016-05-11 | Yeda Research and Development Co. Ltd. | Recombinant protein production in heterologous systems |
WO2011112570A1 (en) | 2010-03-08 | 2011-09-15 | Monsanto Technology Llc | Polynucleotide molecules for gene regulation in plants |
US20120329089A1 (en) | 2010-03-11 | 2012-12-27 | Jacob Edrei | Methods of generating hydrogen |
WO2011125015A2 (en) | 2010-04-05 | 2011-10-13 | Bar-Ilan University | Protease-activatable pore-forming polypeptides |
WO2011128895A2 (en) | 2010-04-12 | 2011-10-20 | Ben Gurion University Of The Negev Research And Development Authority | Sulfotransferase of a red microalga and uses thereof |
US8927274B2 (en) | 2010-04-12 | 2015-01-06 | Technion Research & Development Foundation Limited | Populations of pancreatic progenitor cells and methods of isolating and using same |
EP2561356B1 (en) | 2010-04-18 | 2016-08-03 | Yeda Research and Development Co. Ltd. | MOLECULES AND METHODS OF USING SAME FOR TREATING ErbB/ErbB LIGANDS ASSOCIATED DISEASES |
AU2011246876B2 (en) | 2010-04-28 | 2016-06-23 | Evogene Ltd. | Isolated polynucleotides and polypeptides, and methods of using same for increasing plant yield and/or agricultural characteristics |
US20130053277A1 (en) | 2010-05-04 | 2013-02-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of identifying inhibitors of polypeptides-of-interest |
EP2566500B1 (en) | 2010-05-05 | 2017-04-12 | Rappaport Family Institute for Research in the Medical Sciences | Ccl1 for use in therapy |
IL208820A0 (en) | 2010-10-19 | 2011-01-31 | Rachel Teitelbaum | Biologic female contraceptives |
PL2569417T3 (pl) | 2010-05-13 | 2018-12-31 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Izolowane populacje dorosłych komórek nerkowych i sposoby ich izolowania i stosowania |
DK2390664T3 (da) | 2010-05-25 | 2013-07-22 | Fraunhofer Ges Forschung | Fremgangsmåde til elektrokemisk påvisning af bindingsreaktioner |
CA2800257C (en) | 2010-05-26 | 2019-03-05 | The Board Of Trustees Of The University Of Illinois | Personal glucose meters for detection and quantification of a broad range of analytes |
EP2575859B1 (en) | 2010-06-03 | 2018-09-19 | Ramot at Tel Aviv University, Ltd. | Methods of treating diabetes and compositions capable of same |
CN102933723A (zh) | 2010-06-07 | 2013-02-13 | 奥斯娜特·阿舒尔-费边 | 用于诊断与缺氧有关的病状的方法和试剂盒 |
WO2011158243A2 (en) | 2010-06-16 | 2011-12-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of diagnosing and treating cancer |
US20130097731A1 (en) | 2010-06-16 | 2013-04-18 | Futuragene Israel Ltd. | Pest-resistant plants containing a combination of a spider toxin and a chitinase |
EP2593468B1 (en) | 2010-07-12 | 2020-06-10 | The State of Israel, Ministry of Agriculture and Rural Development, Agricultural Research Organization, (A.R.O.), Volcani Center | Isolated polynucleotides and methods and plants using same for regulating plant acidity |
JP2013535963A (ja) | 2010-07-15 | 2013-09-19 | テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド | Mhcクラスiiと糖尿病関連自己抗原性ペプチドとの天然型複合体に対するt細胞受容体様特異性を有する単離された高親和性実体 |
JP2013538555A (ja) | 2010-07-15 | 2013-10-17 | テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド | Mhcクラスiiとグルタミン酸デカルボキシラーゼ(gad)自己抗原性ペプチドとの天然型複合体に対するt細胞受容体様特異性を有する単離された高親和性実体 |
BR112013000984A2 (pt) | 2010-07-15 | 2017-10-03 | Technion Res & Dev Foundation | Estrutura de ácido nucleico para o aumento da tolerância ao estresse abiótico em plantas |
EP2595637B1 (en) | 2010-07-22 | 2017-11-01 | Cellect Biotherapeutics Ltd. | Regulatory immune cells with enhanced targeted cell death effect |
US9144585B2 (en) | 2010-07-27 | 2015-09-29 | Technion Research & Development Foundation Limited | Isolated mesenchymal progenitor cells and extracellular matrix produced thereby |
WO2012014208A2 (en) | 2010-07-27 | 2012-02-02 | Yeda Research And Development Co. Ltd. | Methods and systems for assessing clonality of cell cultures |
US20130130387A1 (en) | 2010-07-27 | 2013-05-23 | Technion Research & Development Foundation Limited | Method for generating induced pluripotent stem cells from keratinocytes derived from plucked hair follicles |
EP2600885A2 (en) | 2010-08-04 | 2013-06-12 | Ramot at Tel Aviv University, Ltd. | Methods of treating autoimmune diseases of the central nervous system (cns) and neurodegenerative diseases |
US9394523B2 (en) | 2010-08-22 | 2016-07-19 | Ramot At Tel-Aviv University Ltd. | Induced pluripotent stem cells derived from human pancreatic beta cells |
WO2012025925A1 (en) | 2010-08-24 | 2012-03-01 | Rappaport Family Institute For Research In The Medical Sciences | Methods of improving transplantation using sdf-1alpha |
BR112013004851A2 (pt) | 2010-08-30 | 2016-06-07 | Evogene Ltd | método de aumento de eficiência do uso de nitrogênio, rendimento, biomassa, taxa de crescimento, vigor, conteúdo de óleo, rendimento da fibra e/ou tolerância ao estresse abiótico de uma planta, polinucleotídeo isolado, estrutura de ácido nucleio, polipeptídeo isolado, célula vegetal e planta transgêncica |
US20130164288A1 (en) | 2010-09-07 | 2013-06-27 | Protalix Ltd. | Readthrough acetylcholinesterase (ache-r) for treating or preventing parkinson's disease |
CA3150342A1 (en) | 2010-09-07 | 2012-03-15 | Technion Research & Development Foundation Limited | Novel methods and culture media for culturing pluripotent stem cells |
WO2012032510A1 (en) | 2010-09-07 | 2012-03-15 | Yeda Research And Development Co. Ltd. | Primers for amplifying dna and methods of selecting same |
WO2012032519A2 (en) | 2010-09-07 | 2012-03-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of diagnosing parkinson's disease |
EP2613801B1 (en) | 2010-09-08 | 2016-06-08 | Yeda Research and Development Co. Ltd. | Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment |
EP2614083A2 (en) | 2010-09-08 | 2013-07-17 | Yeda Research and Development Co. Ltd | An immunosuppressive drug combination for a stable and long term engraftment |
CN103210082A (zh) | 2010-09-15 | 2013-07-17 | 雷蒙特亚特特拉维夫大学有限公司 | 扩增胰岛β细胞和使其再分化的方法 |
US20130210901A1 (en) | 2010-09-20 | 2013-08-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of treating neurodegenerative diseases |
EP3075396A1 (en) | 2010-10-17 | 2016-10-05 | Yeda Research and Development Co. Ltd. | Methods and compositions for the treatment of insulin-associated medical conditions |
WO2012052878A1 (en) | 2010-10-19 | 2012-04-26 | Vascular Biogenics Ltd. | Isolated polynucleotides and nucleic acid constructs for directing expression of a gene-of-interest in cells |
US20130216603A1 (en) | 2010-10-27 | 2013-08-22 | Nanocyte (Israel) Ltd. | Pharmaceutical compositions and delivery devices comprising stinging cells or capsules |
ES2688457T3 (es) | 2010-10-28 | 2018-11-02 | Yeda Research And Development Co. Ltd. | Métodos de generación de anticuerpos contra metaloenzimas |
UY33705A (es) | 2010-11-03 | 2012-04-30 | Yissum Res Dev Co | Plantas transgenicas con rendimientos de sacarificacion mejorados y metodos para generarlas |
WO2012059925A2 (en) | 2010-11-04 | 2012-05-10 | Ben-Gurion University Of The Negev Research And Development Authority | Acyl-coa: diacylglycerol acyltransferase 1-like gene (ptdgat1) and uses thereof |
WO2012066549A1 (en) | 2010-11-15 | 2012-05-24 | Ramot At Tel-Aviv University Ltd. | Dipeptide analogs for treating conditions associated with amyloid fibril formation |
EP2640404B1 (en) | 2010-11-17 | 2017-02-22 | Ben Gurion University of The Negev Research and Development Authority | T-cell therapy to neurodegenerative diseases |
JP6139410B2 (ja) | 2010-12-02 | 2017-05-31 | テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド | 角膜細胞の作製方法および該角膜細胞を含む細胞集団 |
US20120183960A1 (en) | 2010-12-07 | 2012-07-19 | Enterologics, Inc. | Method for identifying e. coli m-17 |
US9404087B2 (en) | 2010-12-15 | 2016-08-02 | Kadimastem Ltd. | Insulin producing cells derived from pluripotent stem cells |
BR122021002248B1 (pt) | 2010-12-22 | 2022-02-15 | Evogene Ltd | Método para aumentar a tolerância ao estresse abiótico, produção, biomassa, e/ou taxa de crescimento de uma planta |
AU2011350620B2 (en) | 2010-12-28 | 2017-03-02 | Kamedis Ltd. | Plant extracts for the treatment and prevention of infections |
EP2665814B1 (en) | 2011-01-20 | 2017-05-17 | Protalix Ltd. | Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells |
WO2012104851A1 (en) | 2011-01-31 | 2012-08-09 | Yeda Research And Development Co. Ltd. | Methods of diagnosing disease using overlap extension pcr |
WO2012114339A1 (en) | 2011-02-23 | 2012-08-30 | Rappaport Family Institute For Research In The Medical Sciences | High affinity molecules capable of binding a type a plexin receptor and uses of same |
CN103597078B (zh) | 2011-03-02 | 2016-12-14 | 富途锐基尼以色列有限公司 | 具有功能失调的t3ss蛋白的抗菌性转基因植物 |
WO2012117373A1 (en) | 2011-03-03 | 2012-09-07 | Ramot At Tel-Aviv University Ltd. | Genetically modified muscle cells which express neurotrophic factors |
CN103597073B (zh) | 2011-03-06 | 2019-06-07 | 默克雪兰诺有限公司 | 低岩藻糖细胞系及其应用 |
WO2012120518A1 (en) | 2011-03-08 | 2012-09-13 | Ramot At Tel-Aviv University Ltd. | Compositions and methods for diagnosing and treating phenylketonuria (pku) |
EP2685976B1 (en) | 2011-03-17 | 2017-12-27 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Quinolone analogs for treating autoimmune diseases |
AU2012227883A1 (en) | 2011-03-17 | 2013-10-24 | Ramot At Tel-Aviv University Ltd. | Bi- and monospecific, asymmetric antibodies and methods of generating the same |
KR101903339B1 (ko) | 2011-03-22 | 2018-10-01 | 플루리스템 리미티드 | 방사선 또는 화학적 손상을 치료하는 방법 |
MX2013010910A (es) | 2011-03-24 | 2014-03-27 | Neurim Pharma 1991 | Peptidos neuroprotectores. |
WO2012131680A2 (en) | 2011-03-28 | 2012-10-04 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating inflammation |
WO2012137202A1 (en) | 2011-04-05 | 2012-10-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Composition comprising an iron indicator attached to a microparticle and uses of same for quantifying non-transferrin bound iron (ntbi) and cellular labile iron (lci) |
DK2694962T3 (da) | 2011-04-06 | 2017-06-12 | Ramot At Tel-Aviv Univ Ltd | Fremgangsmåder til monitorering og analyse af profiler for metabolisk aktivitet samt diagnostiske og terapeutiske anvendelser deraf |
WO2012142164A1 (en) | 2011-04-12 | 2012-10-18 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii |
WO2012140519A2 (en) | 2011-04-15 | 2012-10-18 | Pluristem Ltd. | Methods and systems for harvesting cells |
WO2012150598A2 (en) | 2011-05-03 | 2012-11-08 | Evogene Ltd. | Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency |
WO2012150600A2 (en) | 2011-05-04 | 2012-11-08 | Ramot At Tel-Aviv University Ltd. | Regulation of amyloid beta molecular composition for the treatment of alzheimer's disease |
WO2012153333A1 (en) | 2011-05-09 | 2012-11-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Regeneration and repair of mesenchymal tissue using amelogenin |
WO2012153336A2 (en) | 2011-05-12 | 2012-11-15 | Rakuto Bio Technologies Ltd. | Methods and device for lightening skin complexion |
WO2012156976A1 (en) | 2011-05-16 | 2012-11-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of producing artemisinin in non-host plants and vectors for use in same |
US20140088017A1 (en) | 2011-05-23 | 2014-03-27 | Yeda Research And Development Co., Ltd. | Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same |
WO2012160526A2 (en) | 2011-05-23 | 2012-11-29 | Ofir Menashe | Formulations of microorganism comprising particles and uses of same |
SG10201604103SA (en) | 2011-05-31 | 2016-07-28 | Hutchison Biofilm Medical Solutions Ltd | Dispersion and detachment of cell aggregates |
US20140113376A1 (en) | 2011-06-01 | 2014-04-24 | Rotem Sorek | Compositions and methods for downregulating prokaryotic genes |
US10166295B2 (en) | 2011-06-02 | 2019-01-01 | Opko Biologics Ltd. | Pegylated OXM variants |
WO2012172555A1 (en) | 2011-06-14 | 2012-12-20 | Yeda Research And Development Co. Ltd. | Combination therapy to prevent dcis formation and progression to breast cancer |
AR086989A1 (es) | 2011-06-23 | 2014-02-05 | Kaiima Bio Agritech Ltd | Trigo comun: sus plantas o partes que tienen un genoma parcial o completamente multiplicado, sus hibridos y productos y metodos para generarlos y utilizarlos |
JP2014520567A (ja) | 2011-07-20 | 2014-08-25 | カイイマ バイオ アグリテック リミテッド | 部分的多重ゲノムまたは完全多重ゲノムを有するトウモロコシ植物およびその使用 |
US20130030452A1 (en) | 2011-07-27 | 2013-01-31 | Health Corporation - Rambam | Devices for surgical applications |
BR112014002737B1 (pt) | 2011-08-04 | 2022-08-02 | Yeda Research And Development Co. Ltd. | Mir-135 |
JP6063613B2 (ja) | 2011-08-09 | 2017-01-18 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | ベータ細胞の分化およびインスリン産生を促進するためのmiR−7のダウンレギュレーション |
WO2013024481A1 (en) | 2011-08-14 | 2013-02-21 | Kaiima Bio Agritech Ltd. | Durum wheat plants having a partially or fully multiplied genome and uses thereof |
WO2013035070A1 (en) | 2011-09-07 | 2013-03-14 | Yeda Research And Development Co. Ltd. | Olfactory signature and odorant mixture having the same |
WO2013035071A1 (en) | 2011-09-08 | 2013-03-14 | Yeda Research And Development Co. Ltd. | Novel risk biomarkers for lung cancer |
EP2753351B1 (en) | 2011-09-08 | 2017-06-21 | Yeda Research and Development Co. Ltd. | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
EP2755467B1 (en) | 2011-09-13 | 2017-07-19 | Monsanto Technology LLC | Methods and compositions for weed control |
UA116089C2 (uk) | 2011-09-13 | 2018-02-12 | Монсанто Текнолоджи Ллс | Спосіб та композиція для боротьби з бур'янами (варіанти) |
CN104160028A (zh) | 2011-09-13 | 2014-11-19 | 孟山都技术公司 | 用于杂草控制的方法和组合物 |
US10760086B2 (en) | 2011-09-13 | 2020-09-01 | Monsanto Technology Llc | Methods and compositions for weed control |
US10806146B2 (en) | 2011-09-13 | 2020-10-20 | Monsanto Technology Llc | Methods and compositions for weed control |
US10829828B2 (en) | 2011-09-13 | 2020-11-10 | Monsanto Technology Llc | Methods and compositions for weed control |
EP3434780A1 (en) | 2011-09-13 | 2019-01-30 | Monsanto Technology LLC | Methods and compositions for weed control |
WO2013054320A1 (en) | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) |
PL2768851T3 (pl) | 2011-10-21 | 2018-05-30 | Augurex Life Sciences Corp. | Antygeny pochodzące z cytrulinowanego białka 14-3-3 oraz ich zastosowania w diagnozie reumatoidalnego zapalenia stawów |
US9145559B2 (en) | 2011-10-27 | 2015-09-29 | Yeda Research And Development Co. Ltd. | Methods of treating cancer |
WO2013067076A2 (en) | 2011-11-03 | 2013-05-10 | Quark Pharmaceuticals, Inc. | Methods and compositions for neuroprotection |
WO2013070821A1 (en) | 2011-11-08 | 2013-05-16 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the nervous system |
US9736998B2 (en) | 2011-11-23 | 2017-08-22 | Danziger Dan Flower Farm | Otomeria plants |
WO2013076730A1 (en) | 2011-11-27 | 2013-05-30 | Yeda Research And Development Co. Ltd. | Methods of regulating angiogenesis and compositions capable of same |
JP2015500279A (ja) | 2011-12-08 | 2015-01-05 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | 哺乳動物胎児肺細胞および該細胞の治療的使用 |
WO2013093921A1 (en) | 2011-12-20 | 2013-06-27 | Collplant Ltd. | Collagen coated synthetic polymer fibers |
EP2794107B1 (en) | 2011-12-22 | 2021-08-11 | Life Technologies Corporation | Sequential lateral flow capillary device for analyte determination |
EP2797421B1 (en) | 2011-12-22 | 2020-05-20 | Yeda Research And Development Co. Ltd. | A combination therapy for a stable and long term engraftment using specific protocols for t/b cell depletion |
EP2797405A1 (en) | 2011-12-28 | 2014-11-05 | Kaiima Bio Agritech Ltd. | Cultivated sorghum plant having a partially or fully multiplied genome and uses of same |
SG11201403756PA (en) | 2012-01-01 | 2014-11-27 | Qbi Entpr Ltd | Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents |
WO2013114363A2 (en) | 2012-01-30 | 2013-08-08 | Yeda Research And Development Co.Ltd. | Antimicrobial agents |
US20150010527A1 (en) | 2012-02-01 | 2015-01-08 | Protalix Ltd. | Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy |
WO2013118120A2 (en) | 2012-02-06 | 2013-08-15 | Rosetta Green Ltd. | Isolated polynucleotides expressing or modulating micrornas or targets of same, transgenic plants comprising same and uses thereof in improving nitrogen use efficiency, abiotic stress tolerance, biomass, vigor or yield of a plant |
CA2863795A1 (en) | 2012-02-13 | 2013-08-22 | Gamida-Cell Ltd. | Culturing of mesenchymal stem cells |
DK3326642T3 (da) | 2012-02-14 | 2021-02-22 | Opko Biologics Ltd | Langtidsvirkende koagulationsfaktorer og brugen deraf |
BR112014021067A2 (pt) | 2012-02-19 | 2018-10-30 | Protalix Ltd | formas unitárias de dosagem oral e usos das mesmas para o tratamento da doença de gaucher |
US9803175B2 (en) | 2012-02-22 | 2017-10-31 | Exostem Biotec Ltd. | Generation of neural stem cells and motor neurons |
JP6329911B2 (ja) | 2012-02-22 | 2018-05-23 | ブレインステム バイオテック リミテッド | 星状膠細胞作製のためのミクロrna |
WO2013128454A1 (en) | 2012-03-01 | 2013-09-06 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization, (A.R.O.), Volcani Center | Male sterile garlic plants, hybrid offspring of same and methods of generating and using same |
US9631028B2 (en) | 2012-03-07 | 2017-04-25 | Yeda Research And Development Co. Ltd. | Compositions for inhibition of quiescin sulfhydryl oxidase (QSOX1) and uses of same |
EP2828280B1 (en) | 2012-03-22 | 2018-05-02 | Ramot at Tel-Aviv University Ltd. | Plif multimeric peptides and uses thereof |
CA2868238A1 (en) | 2012-04-18 | 2013-10-24 | Ramot At Tel Aviv University Ltd. | Lipidated glycosaminoglycan particles for the delivery of nucleic acids |
BR112014025951A2 (pt) | 2012-04-19 | 2017-07-11 | Opko Biologics Ltd | variantes de oxintomodulina de longa ação e métodos de produção do mesmo |
EP2841084B1 (en) | 2012-04-24 | 2018-05-30 | Biokine Therapeutics Ltd. | Cxcr4 antagonist peptide for use in the treatment of large cell lung cancer |
ES2627816T3 (es) | 2012-05-09 | 2017-07-31 | Yeda Research And Development Co. Ltd. | Variantes del pro-dominio de tace como inhibidor de TNF-a y su uso médico |
US8865158B2 (en) | 2012-05-22 | 2014-10-21 | Ramot At Tel-Aviv University Ltd. | Bacteriophages for reducing toxicity of bacteria |
MX360866B (es) | 2012-05-24 | 2018-11-09 | A B Seeds Ltd | Composiciones y métodos para silenciar la expresión genética. |
JP5868549B2 (ja) | 2012-05-24 | 2016-02-24 | マウントゲイト グループ リミテッド | 狂犬病感染の予防および治療に関する組成物および方法 |
WO2013183048A1 (en) | 2012-06-03 | 2013-12-12 | Ben-Gurion University Of The Negev Research And Development Authority | Functionalized titanium binding peptides and implants coated with same |
CN109096387B (zh) | 2012-06-04 | 2021-11-30 | 奥普科生物制品有限公司 | 聚乙二醇化的oxm变体 |
US10023474B2 (en) | 2012-07-03 | 2018-07-17 | Nanospun Technologies Ltd. | Methods for adsorption and biodegradation of petroleum |
US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
US9175266B2 (en) | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
DK2880155T3 (da) | 2012-07-29 | 2019-07-15 | Yeda Res & Dev | Anvendelse af den reduktive glycinvej til generering af formatotrofiske og autotrofiske mikroorganismer |
CN104684558A (zh) | 2012-07-31 | 2015-06-03 | 耶达研究及发展有限公司 | 诊断和治疗运动神经元疾病的方法 |
JP6362596B2 (ja) | 2012-08-06 | 2018-07-25 | ブレインストーム セル セラペウティクス リミテッド | 神経栄養因子を分泌する間葉系幹細胞の作製方法 |
US20140068814A1 (en) | 2012-09-03 | 2014-03-06 | A.B. Seeds Ltd. | Method of improving abiotic stress tolerance of plants and plants generated thereby |
US10543278B2 (en) | 2012-09-12 | 2020-01-28 | Ramot At Tel-Aviv University Ltd. | Immunoparticles and methods of generating and using same |
EP2906954B1 (en) | 2012-10-09 | 2018-04-11 | Ramot at Tel-Aviv University Ltd. | Methods and kits for predicting prognosis of cancer using soluble mortalin in blood |
US20150266970A1 (en) | 2012-10-24 | 2015-09-24 | Yeda Research And Development Co. Ltd. | Combinations of epidermal growth factor receptor targeting antibodies for treating cancer |
WO2014068553A1 (en) | 2012-10-29 | 2014-05-08 | Yeda Research And Development Co. Ltd. | Aptamers, multimeric aptamers and uses thereof |
CN112661863A (zh) | 2012-11-20 | 2021-04-16 | 奥普科生物制品有限公司 | 通过连接至促性腺激素羧基端肽来增加多肽的流体动力学体积的方法 |
MX2015004626A (es) | 2012-11-29 | 2015-07-14 | Yeda Res & Dev | Metodos para prevenir metastasis de tumor, tratar y pronosticar cancer e identificar agentes que son inhibidores putativos de metastasis. |
WO2015079413A2 (en) | 2013-11-28 | 2015-06-04 | Yeda Research And Development Co. Ltd. | Synaptojanin-2 inhibitors and uses thereof |
US10683505B2 (en) | 2013-01-01 | 2020-06-16 | Monsanto Technology Llc | Methods of introducing dsRNA to plant seeds for modulating gene expression |
UY35251A (es) | 2013-01-01 | 2014-07-31 | Seeds Ltd Ab | MOLÉCULAS DE dsRNA AISLADAS Y MÉTODOS PARA USARLAS PARA SILENCIAR MOLÉCULAS DIANA DE INTERÉS |
WO2014108854A1 (en) | 2013-01-09 | 2014-07-17 | Fusimab Ltd. | Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies |
WO2014108850A2 (en) | 2013-01-09 | 2014-07-17 | Yeda Research And Development Co. Ltd. | High throughput transcriptome analysis |
WO2014111936A1 (en) | 2013-01-17 | 2014-07-24 | Novellusdx Ltd. | Methods and systems for identifying patient specific driver mutations |
WO2014118785A1 (en) | 2013-02-04 | 2014-08-07 | Ramot At Tel-Aviv University Ltd. | Generation of cytotoxic tumor specific cell lines and uses thereof |
CA2902727C (en) | 2013-03-06 | 2020-08-18 | Protalix Ltd. | Use of plant cells expressing a tnfalpha polypeptide inhibitor in therapy |
US20160017021A1 (en) | 2013-03-06 | 2016-01-21 | Protalix Ltd. | TNF alpha INHIBITOR POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME, CELLS EXPRESSING SAME AND METHODS OF PRODUCING SAME |
WO2014164797A2 (en) | 2013-03-13 | 2014-10-09 | Monsanto Technology Llc | Methods and compositions for weed control |
UY35379A (es) | 2013-03-13 | 2014-09-30 | Monsanto Technology Llc | ?métodos y composiciones para el control de malezas?. |
US10568328B2 (en) | 2013-03-15 | 2020-02-25 | Monsanto Technology Llc | Methods and compositions for weed control |
ES2883580T3 (es) | 2013-03-21 | 2021-12-09 | Collplant Ltd | Composiciones que comprenden colágeno y PRP para la regeneración de tejidos y su método de producción |
CN105163749B (zh) | 2013-03-24 | 2018-03-27 | 拜欧肯治疗有限公司 | 治疗骨髓性白血病的方法 |
BR112015026702A2 (pt) | 2013-04-21 | 2018-02-06 | Yeda Res And Developmente Co Ltd | métodos de extermínio de células senescentes |
ES2831424T3 (es) | 2013-04-23 | 2021-06-08 | Yeda Res & Dev | Células madre pluripotentes naif aisladas y métodos para generarlas |
CN105555796B (zh) | 2013-04-25 | 2019-09-17 | 耶达研究及发展有限公司 | 抑制肽对治疗炎性疾病的用途 |
WO2014188423A1 (en) | 2013-05-21 | 2014-11-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Treatment of mast cell related pathologies |
WO2014191995A2 (en) | 2013-05-27 | 2014-12-04 | Rakuto Bio Technologies Ltd. | Enzymatic system-containing cosmetic compositions |
WO2014207744A1 (en) | 2013-06-24 | 2014-12-31 | Ramot At Tel-Aviv University Ltd. | Omentum based scaffold and delivery system |
US9850496B2 (en) | 2013-07-19 | 2017-12-26 | Monsanto Technology Llc | Compositions and methods for controlling Leptinotarsa |
MX359191B (es) | 2013-07-19 | 2018-09-18 | Monsanto Technology Llc | Composiciones y métodos para controlar leptinotarsa. |
WO2015015489A1 (en) | 2013-07-30 | 2015-02-05 | Biolinerx Ltd. | Antibody for treating diabetes and autoimmune diseases |
CN105849117B (zh) | 2013-08-29 | 2017-12-12 | 耶达研究及发展有限公司 | Na,K‑ATP酶的α2亚型的选择性抑制剂和用于降低眼内压的用途 |
WO2015033343A1 (en) | 2013-09-03 | 2015-03-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Compositions and methods for expressing recombinant polypeptides |
IL228284A (en) | 2013-09-03 | 2016-12-29 | Technion Res & Dev Foundation | Implants from cellular scaffolding and blood vessel stalk |
WO2015033344A1 (en) | 2013-09-05 | 2015-03-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods and kits for inhibiting pathogenicity of group a streptococcus (gas) or group g streptococcus (ggs) |
WO2015037009A1 (en) | 2013-09-16 | 2015-03-19 | Plexicure Ltd. | Isolated proteins capable of binding plexin-a4 and methods of producing and using same |
WO2015040609A1 (en) | 2013-09-17 | 2015-03-26 | Yeda Research And Development Co. Ltd. | Erk-derived peptides and uses thereof |
US20160237404A1 (en) | 2013-10-01 | 2016-08-18 | Kadimastem Ltd. | Directed differentiation of astrocytes from human pluripotent stem cells for use in drug screening and the treatment of amyotrophic laterial sclerosis (als) |
DK3060239T3 (da) | 2013-10-21 | 2020-08-03 | Opko Biologics Ltd | Langtidsvirkende polypeptider og fremgangsmåder til fremstilling og indgivelse heraf |
US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
WO2015059690A1 (en) | 2013-10-24 | 2015-04-30 | Yeda Research And Development Co. Ltd. | Polynucleotides encoding brex system polypeptides and methods of using s ame |
CA2928315C (en) | 2013-10-31 | 2023-03-21 | Biokine Therapeutics Ltd. | Methods of treating acute myeloid leukemia with a flt3 mutation |
UA120426C2 (uk) | 2013-11-04 | 2019-12-10 | Монсанто Текнолоджі Елелсі | Композиція та спосіб для боротьби з членистоногими паразитами та зараженням шкідниками |
EP3074391B1 (en) | 2013-11-28 | 2019-07-31 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Rna polymerase i inhibitors and uses thereof |
UA119253C2 (uk) | 2013-12-10 | 2019-05-27 | Біолоджикс, Інк. | Спосіб боротьби із вірусом у кліща varroa та у бджіл |
ES2697757T3 (es) | 2013-12-10 | 2019-01-28 | Yeda Res & Dev | Uso de enzimas que catalizan la síntesis de piruvato a partir de formiato y acetil-CoA y bacterias que expresan la misma |
EP3116303B1 (en) | 2014-01-15 | 2020-07-22 | Monsanto Technology LLC | Methods and compositions for weed control using epsps polynucleotides |
WO2015114633A1 (en) | 2014-01-30 | 2015-08-06 | Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd. | Actin binding peptides and compositions comprising same for inhibiting angiogenes is and treating medical conditions associated with same |
CN111068053A (zh) | 2014-02-03 | 2020-04-28 | 耶路撒冷希伯来大学的益生研究开发有限公司 | 使用酪蛋白激酶i抑制剂以消耗干细胞的用途 |
CN106715695B (zh) | 2014-02-05 | 2020-07-31 | 耶达研究及发展有限公司 | 用于治疗和诊断的微rna和包含所述微rna的组合物 |
EP3102607B1 (en) | 2014-02-06 | 2018-08-22 | Yeda Research and Development Co. Ltd. | Anti cd84 antibodies, compositions comprising same and uses thereof |
US20170101633A1 (en) | 2014-02-10 | 2017-04-13 | Protalix Ltd. | Method of maintaining disease stability in a subject having gaucher's disease |
JP6628253B2 (ja) | 2014-02-11 | 2020-01-08 | ブレインストーム セル セラペウティクス リミテッド | 細胞の適性を判定する方法 |
EP3114483A1 (en) | 2014-03-03 | 2017-01-11 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | Method and device for detection of pseudomonas aeruginosa |
EP2923709A1 (en) | 2014-03-28 | 2015-09-30 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Multi-component-multistage malaria vaccine |
WO2015153339A2 (en) | 2014-04-01 | 2015-10-08 | Monsanto Technology Llc | Compositions and methods for controlling insect pests |
CA2945438C (en) | 2014-04-10 | 2023-08-22 | Bonus Therapeutics Ltd. | Bone repair compositions |
PT4026917T (pt) | 2014-04-14 | 2024-02-12 | Yissum Research And Development Company Of The Hebrew Univ Of Jerusalem Ltd | Método e kit para determinar a morte de células ou de tecido ou a origem de tecidos ou de células de dna por análise de metilação do dna |
EP3132057B1 (en) | 2014-04-17 | 2019-10-16 | Yeda Research and Development Co. Ltd. | Methods and kits for analyzing dna binding moieties attached to dna |
US11427647B2 (en) | 2014-04-27 | 2022-08-30 | Famewave Ltd. | Polynucleotides encoding humanized antibodies against CEACAM1 |
EP3766902A1 (en) | 2014-04-27 | 2021-01-20 | FameWave Ltd. | Humanized antibodies against ceacam1 |
CN106460048B (zh) | 2014-04-28 | 2021-01-05 | 耶达研究及发展有限公司 | 针对试剂的微生物组应答 |
WO2015170324A2 (en) | 2014-05-04 | 2015-11-12 | Forrest Innovations Ltd. | Compositions for mosquito control and uses of same |
EP3145947A2 (en) | 2014-05-22 | 2017-03-29 | Yeda Research and Development Co., Ltd. | Recombinant microorganisms capable of carbon fixation |
US20170095512A1 (en) | 2014-06-02 | 2017-04-06 | Kadimastem Ltd. | Methods of inducing myelination and maturation of oligodendrocytes |
US20170253881A1 (en) | 2014-06-02 | 2017-09-07 | Technion Research & Development Foundation Limited | Compositions and methods of selectively inhibiting irp1 and treating inflammation |
CA2953347A1 (en) | 2014-06-23 | 2015-12-30 | Monsanto Technology Llc | Compositions and methods for regulating gene expression via rna interference |
WO2015198320A1 (en) | 2014-06-24 | 2015-12-30 | Insight Biopharmaceuticals Ltd. | Methods of purifying antibodies |
EP3161138A4 (en) | 2014-06-25 | 2017-12-06 | Monsanto Technology LLC | Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression |
JP6587288B2 (ja) | 2014-06-25 | 2019-10-09 | テル ハショマー メディカル リサーチ インフラストラクチャー アンド サーヴィシーズ リミテッド | がん幹細胞の同定ならびに診断および処置のためのその使用 |
WO2015198326A1 (en) | 2014-06-26 | 2015-12-30 | Ramot At Tel-Aviv University Ltd. | Liposomal formulations for delivery of nucleic acids |
WO2016005985A2 (en) | 2014-07-09 | 2016-01-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method for reprogramming cells |
HUE049261T2 (hu) | 2014-07-15 | 2020-09-28 | Yissum Research And Development Company Of The Hebrew Univ Of Jerusalem Ltd | CD44 izolált polipeptidek és alkalmazásaik |
CA2955414A1 (en) | 2014-07-21 | 2016-01-28 | Novellusdx Ltd. | Methods and systems for determining oncogenic index of patient specific mutations |
JP6700249B2 (ja) | 2014-07-21 | 2020-06-10 | ノベルラスディクス リミテッド | 患者特有の変異の薬物応答を測定する方法 |
CN114009454A (zh) | 2014-07-29 | 2022-02-08 | 孟山都技术公司 | 用于控制昆虫害虫的组合物和方法 |
US11920164B2 (en) | 2014-07-30 | 2024-03-05 | Yeda Research And Development Co. Ltd. | Media for culturing naive human pluripotent stem cells |
EP3699930B1 (en) | 2014-08-14 | 2024-02-07 | MeMed Diagnostics Ltd. | Computational analysis of biological data using manifold and a hyperplane |
WO2016030899A1 (en) | 2014-08-28 | 2016-03-03 | Yeda Research And Development Co. Ltd. | Methods of treating amyotrophic lateral scleroses |
AU2015313811A1 (en) | 2014-09-08 | 2017-04-06 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (TKI) |
WO2016038609A1 (en) | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Anti-her3 antibodies and uses of same |
EP2992895A1 (en) | 2014-09-08 | 2016-03-09 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Three-component-multistage malaria vaccine |
IL234638A0 (en) | 2014-09-14 | 2014-12-02 | Yeda Res & Dev | NMDA receptor antagonists for the treatment of Gaucher disease |
CN106999608A (zh) | 2014-09-21 | 2017-08-01 | 耶路撒冷希伯来大学伊森姆研究发展公司 | 为了治疗脂质相关病症而下调mir‑132 |
EP3209799B1 (en) | 2014-10-20 | 2020-07-08 | Gen-Probe Incorporated | Red blood cell lysis solution |
ES2965744T3 (es) | 2014-11-13 | 2024-04-16 | Enzootic Holdings Ltd | Inversión sexual funcional de crustáceos decápodos hembras |
CA2967233A1 (en) | 2014-11-17 | 2016-05-26 | Yeda Research And Development Co. Ltd. | Method of analyzing microbiome |
US20180042994A1 (en) | 2014-11-17 | 2018-02-15 | Yeda Research And Development Co. Ltd. | Methods of treating diseases related to mitochondrial function |
WO2016079739A2 (en) | 2014-11-20 | 2016-05-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Compositions and methods for producing polypeptides with a modified glycosylation pattern in plant cells |
JP6860483B2 (ja) | 2014-11-26 | 2021-04-14 | テクノロジー イノベーション モメンタム ファンド(イスラエル)リミテッド パートナーシップTechnology Innovation Momentum Fund(israel)Limited Partnership | 細菌遺伝子の標的化削減 |
KR20170081268A (ko) | 2014-11-27 | 2017-07-11 | 단지거 이노베이션즈 엘티디. | 게놈 편집용 핵산 구조체 |
WO2016092555A2 (en) | 2014-12-11 | 2016-06-16 | Yeda Research And Development Co. Ltd. | Isolated phosphotriesterase polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage |
WO2016103269A1 (en) | 2014-12-23 | 2016-06-30 | Ramot At Tel-Aviv University Ltd. | Populations of neural progenitor cells and methods of producing and using same |
EP3916085A1 (en) | 2014-12-30 | 2021-12-01 | Cell Cure Neurosciences Ltd. | Assessing retinal pigment epithelial cell populations |
IL305070A (en) | 2014-12-30 | 2023-10-01 | Cell Cure Neurosciences Ltd | RPE cell populations and methods for their production |
WO2016108219A1 (en) | 2014-12-30 | 2016-07-07 | Cell Cure Neurosciences Ltd. | Methods of treating retinal diseases |
EP3240896A1 (en) | 2015-01-04 | 2017-11-08 | Protalix Ltd. | Modified dnase and uses thereof |
WO2016116935A1 (en) | 2015-01-21 | 2016-07-28 | Yeda Research And Development Co. Ltd. | Use of rasa2 as a prognostic and therapeutic marker for melanoma |
PL3256589T3 (pl) | 2015-01-22 | 2022-02-21 | Monsanto Technology Llc | Kompozycje i sposoby kontrolowania leptinotarsa |
WO2016135732A1 (en) | 2015-02-26 | 2016-09-01 | Yeda Research And Development Co. Ltd. | Method of promoting hair growth |
EP3268475B1 (en) | 2015-03-11 | 2020-10-21 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | Decoy oligonucleotides for the treatment of diseases |
IL237852A0 (en) | 2015-03-19 | 2016-03-24 | Yeda Res & Dev | Antibodies against amphigoline, medical preparations containing them and their use |
ES2904573T3 (es) | 2015-03-27 | 2022-04-05 | Univ Southern California | Terapia con células T dirigida a LHR para el tratamiento de tumores sólidos |
EP4218771A1 (en) | 2015-03-27 | 2023-08-02 | Yeda Research and Development Co. Ltd | Methods of treating motor neuron diseases |
RU2017135552A (ru) | 2015-03-31 | 2019-04-30 | Иеда Рисеч Энд Девелопмент Ко. Лтд. | Глутамат оксалоацетат трансаминаза 1 (got1), препараты и способы их получения и применения |
EP3277260B1 (en) | 2015-04-01 | 2021-05-12 | The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) | Erodium crassifolium l'her plant extracts and uses thereof |
CA2981732C (en) | 2015-04-07 | 2024-03-12 | Boris Khalfin | Compositions for treating and/or preventing cell or tissue necrosis specifically targeting cathepsin c and/or cela1 and/or cela3a and/or structurally related enzymes thereto |
EP3081575A1 (en) | 2015-04-12 | 2016-10-19 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Anti-plasmodium parasite antibodies |
CA2986202C (en) | 2015-04-27 | 2023-08-22 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | Egr1 targeting molecules for the treatment of inflammatory and hyperproliferative conditions |
AU2016255724B2 (en) | 2015-04-29 | 2020-05-14 | The State of Israel, Ministry of Agriculture and Rural Development Agricultural Research Organization (ARO) (Volcani Center) | Anti-phytopathogenic compositions |
US20190031759A1 (en) | 2015-04-30 | 2019-01-31 | Technion Research & Development Foundation Limited | Chimeric antigen receptors and methods of their use |
US11845928B2 (en) | 2015-05-04 | 2023-12-19 | Tsinghua University | Methods and kits for fragmenting DNA |
EP3294280A1 (en) | 2015-05-11 | 2018-03-21 | Yeda Research and Development Co., Ltd. | Citrin inhibitors for the treatment of cancer |
WO2016185471A1 (en) | 2015-05-17 | 2016-11-24 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | Compositions and methods for treating cancer |
WO2016185457A1 (en) | 2015-05-19 | 2016-11-24 | Yeda Research And Development Co. Ltd. | Methods of promoting lymphangiogenesis |
WO2016185481A2 (en) | 2015-05-20 | 2016-11-24 | Yeda Research And Development Co. Ltd. | Method of targeting senescent cells |
JP2018515564A (ja) | 2015-05-21 | 2018-06-14 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッドYeda Research And Development Co.Ltd. | 健康増進のための細菌群 |
MX2017015375A (es) | 2015-05-29 | 2018-06-19 | Opko Biologics Ltd | Variantes de oxintomodulina pegilada. |
AU2016270870A1 (en) | 2015-06-02 | 2018-01-04 | Monsanto Technology Llc | Compositions and methods for delivery of a polynucleotide into a plant |
AU2016270913A1 (en) | 2015-06-03 | 2018-01-04 | Monsanto Technology Llc | Methods and compositions for introducing nucleic acids into plants |
JP7010473B2 (ja) | 2015-06-04 | 2022-02-10 | ユニバーシティ オブ サザン カリフォルニア | Lym-1およびlym-2標的化car細胞免疫療法 |
NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
WO2016203476A1 (en) | 2015-06-18 | 2016-12-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods and compositions for diagnosing and treating urothelial cancer |
EP4026563A1 (en) | 2015-06-18 | 2022-07-13 | Yeda Research and Development Co. Ltd | Conditioning protocols and use of same for tissue regeneration |
EP3310347B1 (en) | 2015-06-19 | 2021-08-04 | OPKO Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
US10933124B2 (en) | 2015-07-16 | 2021-03-02 | Yeda Research And Development Co. Ltd. | Methods of transplantation and disease treatment |
KR20180063881A (ko) | 2015-07-16 | 2018-06-12 | 바이오카인 테라퓨틱스 리미티드 | 암 치료용 조성물 및 방법 |
EP3325494B1 (en) | 2015-07-19 | 2020-12-30 | Yeda Research and Development Co., Ltd. | Selective inhibitors of alpha2-containing isoforms of na,k-atpase and use thereof for reducing intraocular pressure |
BR112018001310A2 (pt) | 2015-07-22 | 2018-09-11 | Phytopharma Int Ltd | composições ingeríveis por abelha, métodos de uso das mesmas para a produção de mel e mel produzido por estas |
US11230696B2 (en) | 2015-07-29 | 2022-01-25 | Hadasit Medical Research Services And Development Ltd. | Large scale production of retinal pigment epithelial cells |
US20180221393A1 (en) | 2015-08-03 | 2018-08-09 | Biokine Therapeutics Ltd. | Cxcr4 binding agents for treatment of diseases |
EP3332009A1 (en) | 2015-08-04 | 2018-06-13 | Yeda Research and Development Co., Ltd. | Methods of screening for riboswitches and attenuators |
JP6868608B2 (ja) | 2015-08-05 | 2021-05-12 | セル キュア ニューロサイエンシズ リミテッド | 網膜疾患の処置のための光受容体の調製 |
EP3331994B1 (en) | 2015-08-05 | 2022-09-14 | Cell Cure Neurosciences Ltd. | Preparation of retinal pigment epithelium cells |
US10639350B2 (en) | 2015-08-10 | 2020-05-05 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | Methods and pharmaceutical compositions for improving wound healing using CD24 |
US20180237790A1 (en) | 2015-08-13 | 2018-08-23 | Forrest Innovation Ltd. | Formulations and compositions for delivery of nucleic acids to plant cells |
WO2017033188A1 (en) | 2015-08-24 | 2017-03-02 | Yeda Research And Development Co. Ltd. | Algal oil and biofuel and methods of producing same |
US10765706B2 (en) | 2015-09-03 | 2020-09-08 | University Of South Florida | Method of stem cell delivery into the brain during chronic disease using blood brain barrier permeabilizers |
WO2017042816A1 (en) | 2015-09-10 | 2017-03-16 | Yeda Research And Development Co. Ltd. | Ablation of perforin positive dendritic cells in cancer treatment |
WO2017072757A1 (en) | 2015-10-25 | 2017-05-04 | Yeda Research And Development Co. Ltd. | Antibodies targeting quiescin sulfhydryl oxidase (qsox1) and uses of same |
AU2016347652A1 (en) | 2015-10-26 | 2018-05-24 | Cell Cure Neurosciences Ltd. | Preparation of retinal pigment epithelium cells |
CA3187317A1 (en) | 2015-10-27 | 2017-05-04 | Jay Pharma, Inc. | Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer |
IL242380A0 (en) | 2015-10-29 | 2016-02-01 | Yeda Res & Dev | A method for inducing the division of cardiomyocytes and treating heart diseases |
WO2017077539A1 (en) | 2015-11-03 | 2017-05-11 | Ariel-University Research And Development Company Ltd. | Compositions for regeneration and repair of neural tissue |
US20180327855A1 (en) | 2015-11-11 | 2018-11-15 | Ramot At Tel-Aviv University Ltd. | Methods of detecting 5-hydroxymethylcytosine and diagnosing of cancer |
WO2017094001A1 (en) | 2015-11-30 | 2017-06-08 | Kadimastem Ltd | Methods for differentiating and purifying pancreatic endocrine cells |
EP3176183A1 (en) | 2015-12-02 | 2017-06-07 | Yeda Research and Development Co. Ltd | Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki) |
EP4059507B1 (en) | 2015-12-16 | 2024-06-05 | Ramot at Tel-Aviv University Ltd. | Particles comprising decellularized omentum |
WO2017115367A1 (en) | 2015-12-28 | 2017-07-06 | The National Institute for Biotechnology in the Negev Ltd. | Composition and method for treating amyotrophic lateral sclerosis |
AU2017204950A1 (en) | 2016-01-06 | 2018-08-16 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating malignant, autoimmune and inflammatory diseases |
WO2017122203A1 (en) | 2016-01-11 | 2017-07-20 | Technion Research & Development Foundation Limited | Methods of determining prognosis of sepsis and treating same |
EP3405024B1 (en) | 2016-01-21 | 2022-12-28 | The State of Israel - Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) | Parthenocarpic plants and methods of producing same |
IL243839B (en) | 2016-01-28 | 2018-01-31 | Sp Nano Ltd | Conductive wires |
IL243838A (en) | 2016-01-28 | 2017-07-31 | Sp Nano Ltd | The composition containing sp1 protein and carbon nanoparticles and its uses |
WO2017130205A1 (en) | 2016-01-31 | 2017-08-03 | Hadasit Medical Research Services And Development Ltd. | Autosomal-identical pluripotent stem cell populations having non-identical sex chromosomal composition and uses thereof |
US11230578B2 (en) | 2016-02-04 | 2022-01-25 | Yeda Research And Development Co. Ltd. | Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant P53 |
US20190046497A1 (en) | 2016-02-14 | 2019-02-14 | Yeda Research And Development Co., Ltd. | Methods of modulating protein exocytosis and uses of same in therapy |
EP3414346B1 (en) | 2016-02-14 | 2019-11-13 | Yeda Research and Development Co. Ltd. | Microbiome-based diagnosis, prediction and treatment of relapsing obesity |
MX2018009984A (es) | 2016-02-16 | 2019-01-21 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Análogos no proteínicos de fenilananina para la inhibicion del crecimiento de cianobacterias y plantas. |
WO2017145162A1 (en) | 2016-02-23 | 2017-08-31 | Chaya Brodie | Generation of cancer stem cells and use thereof |
SG11201807437XA (en) | 2016-03-01 | 2018-09-27 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Antibodies specific to human poliovirus receptor (pvr) |
CN108699609A (zh) | 2016-03-03 | 2018-10-23 | 米密德诊断学有限公司 | 分析rna用于诊断感染类型 |
US20190216891A1 (en) | 2016-03-06 | 2019-07-18 | Yeda Research And Development Co., Ltd. | Method for modulating myelination |
IL244649A0 (en) | 2016-03-17 | 2016-06-30 | Yeda Res & Dev | Methods for the isolation of barrel-like proteases and the identification of peptides that are cleaved by Alidan |
US10421785B2 (en) | 2016-04-11 | 2019-09-24 | Bar-Ilan University | Delta receptor agonist peptides and use thereof |
EP3448998B1 (en) | 2016-04-27 | 2020-06-03 | Gen-Probe Incorporated | Blood cell lysis reagent |
CN109475581A (zh) | 2016-05-22 | 2019-03-15 | 耶达研究及发展有限公司 | 为了移植及诱导耐受性而使用肺细胞的方法 |
IL245861A0 (en) | 2016-05-25 | 2016-09-04 | Yeda Res & Dev | Use of substances to treat drug-resistant tumors |
WO2017208247A1 (en) | 2016-06-02 | 2017-12-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Assay for the removal of methyl-cytosine residues from dna |
EP3464322B1 (en) | 2016-06-05 | 2023-04-05 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Novel molecules for the treatment of inflammation |
EP3468610A1 (en) | 2016-06-09 | 2019-04-17 | OPKO Biologics Ltd. | Long-acting oxyntomodulin formulation and methods of producing and administering same |
WO2017221225A1 (en) | 2016-06-19 | 2017-12-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Screening for chemotherapy resistance in human haploid cells |
JP7334043B2 (ja) | 2016-06-27 | 2023-08-28 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッド | メモリーt細胞から作られるベト細胞 |
EP3482200B1 (en) | 2016-07-10 | 2022-05-04 | Memed Diagnostics Ltd. | Protein signatures for distinguishing between bacterial and viral infections |
EP3482201B1 (en) | 2016-07-10 | 2022-12-14 | Memed Diagnostics Ltd. | Early diagnosis of infections |
KR20240006077A (ko) | 2016-07-11 | 2024-01-12 | 옵코 바이오로직스 리미티드 | 지속성 응고 인자 vii 및 그 제조 방법 |
IL246722A0 (en) | 2016-07-11 | 2016-09-29 | Yeda Res & Dev | Combined treatment to increase endogenous synthesis of nitric oxide |
US20190224244A1 (en) | 2016-07-11 | 2019-07-25 | Bonus Therapeutics Ltd. | Cell compositions for tissue regeneration |
EP3481191A2 (en) | 2016-07-11 | 2019-05-15 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | Systems and methods for growing cells in vitro |
EP4434516A2 (en) | 2016-07-18 | 2024-09-25 | Ramot at Tel-Aviv University Ltd. | Modular platform for targeted therapeutics |
WO2018020489A1 (en) | 2016-07-24 | 2018-02-01 | Yeda Research And Development Co. Ltd. | Methods and kits for analyzing dna binding moieties attached to dna |
EP3497231B1 (en) | 2016-08-08 | 2023-10-04 | Technology Innovation Momentum Fund (Israel) Limited Partnership | Bacterial systems for analyzing ubiquitylated polypeptides |
EP3497239A4 (en) | 2016-08-10 | 2020-02-26 | Ramot at Tel-Aviv University Ltd. | METHYLATION STATUS ANALYSIS AND COPY NUMBER |
CN109844532B (zh) | 2016-08-10 | 2022-06-17 | 米密德诊断学有限公司 | 分析生物数据的系统和方法 |
PL3496730T3 (pl) | 2016-08-14 | 2022-09-26 | Ramot At Tel-Aviv University Ltd. | Egzosomy pochodzące z komórek mezenchymalnych do leczenia zaburzeń neurologicznych |
IL247368A0 (en) | 2016-08-18 | 2016-11-30 | Yeda Res & Dev | Diagnostic and therapeutic uses of exosomes |
WO2018037416A1 (en) | 2016-08-25 | 2018-03-01 | Yeda Research And Development Co. Ltd. | Methods and compositions for treating autoimmune diseases |
WO2018047154A1 (en) | 2016-09-07 | 2018-03-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Anti-nkp46 antibodies and therapeutic use of same |
EP3512943B1 (en) | 2016-09-14 | 2023-04-12 | Yeda Research and Development Co. Ltd. | Crisp-seq, an integrated method for massively parallel single cell rna-seq and crispr pooled screens |
WO2018060998A1 (en) | 2016-09-29 | 2018-04-05 | Memed Diagnostics Ltd. | Methods of prognosis and treatment |
IL248468A0 (en) | 2016-10-13 | 2017-01-31 | Technion Res & Dev Foundation | Use of caspase-3 inhibitors and caspase-3 activators in the preparation of medical preparations for cancer treatment and wound healing |
IL248385A0 (en) | 2016-10-18 | 2017-02-01 | Yeda Res & Dev | Treatment of circadian rhythm disorder |
EP3538651A1 (en) | 2016-11-10 | 2019-09-18 | Yeda Research and Development Co., Ltd. | Phosphotriesterases for treating or preventing organophosphate exposure associated damage |
CN110234765A (zh) | 2016-11-28 | 2019-09-13 | 耶达研究及发展有限公司 | 分离的多核苷酸和多肽及使用它们来表达感兴趣的表达产物的方法 |
EP3548015A1 (en) | 2016-11-30 | 2019-10-09 | Yeda Research and Development Co. Ltd. | Methods of treating liver toxicity and disorders |
EP3548106B1 (en) | 2016-12-01 | 2023-01-04 | Ramot at Tel-Aviv University Ltd. | Combined treatment for nerve injuries |
EP3571295A1 (en) | 2017-01-18 | 2019-11-27 | Yeda Research and Development Co. Ltd | Genetically modified veto cells and use of same in immunotherapy |
IL250479A0 (en) | 2017-02-06 | 2017-03-30 | Sorek Rotem | Genetically engineered cells expressing a disarm system that confers resistance to phages and methods for their production |
IL250916A0 (en) | 2017-03-02 | 2017-06-29 | Geiger Benjamin | Methods for growing t cells in culture and their use |
WO2018167780A1 (en) | 2017-03-12 | 2018-09-20 | Yeda Research And Development Co. Ltd. | Methods of prognosing and treating cancer |
US20200150125A1 (en) | 2017-03-12 | 2020-05-14 | Yeda Research And Development Co., Ltd. | Methods of diagnosing and prognosing cancer |
CN118021843A (zh) | 2017-03-16 | 2024-05-14 | 谱系细胞疗法公司 | 用于测量视网膜疾病疗法的疗效的方法 |
CN110678543B (zh) | 2017-04-05 | 2024-04-09 | 耶达研究及发展有限公司 | 体外培养系统及其使用方法 |
IL252151A0 (en) | 2017-05-07 | 2017-07-31 | Fainzilber Michael | Treatment of stress disorders |
KR20200004880A (ko) | 2017-05-10 | 2020-01-14 | 아리엘 싸이언티픽 이노베이션스 엘티디. | 항체를 정제하는 방법 |
WO2018216006A1 (en) | 2017-05-21 | 2018-11-29 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | Combination of markers for diagnosing cancer |
EP3634991A1 (en) | 2017-05-23 | 2020-04-15 | Technion Research & Development Foundation Limited | Agents which inhibit gads dimerization and methods of use thereof |
GB201708665D0 (en) | 2017-05-31 | 2017-07-12 | Tropic Biosciences Uk Ltd | Compositions and methods for increasing extractability of solids from coffee beans |
GB201708662D0 (en) | 2017-05-31 | 2017-07-12 | Tropic Biosciences Uk Ltd | Compositions and methods for increasing shelf-life of banana |
WO2018220582A1 (en) | 2017-05-31 | 2018-12-06 | Tropic Biosciences UK Limited | Methods of selecting cells comprising genome editing events |
WO2018229764A1 (en) | 2017-06-13 | 2018-12-20 | Yeda Research And Development Co. Ltd. | Treatment of advanced or progressive multiple sclerosis |
US11466323B2 (en) | 2017-07-13 | 2022-10-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Dual-probe digital droplet PCR strategy for specific detection of tissue-specific circulating DNA molecules |
EP3652342A1 (en) | 2017-07-13 | 2020-05-20 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | Detecting tissue-specific dna |
EP4403646A2 (en) | 2017-07-13 | 2024-07-24 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | Dna targets as tissue-specific methylation markers |
IL253642A0 (en) | 2017-07-24 | 2017-09-28 | Seger Rony | Combined treatment for cancer |
IL253984A0 (en) | 2017-08-14 | 2017-09-28 | Yeda Res & Dev | Immunotherapy against aranviruses that bind through transferrin receptor 1 (tfr1 |
WO2019038771A1 (en) | 2017-08-23 | 2019-02-28 | Technion Research & Development Foundation Limited | COMPOSITIONS AND METHODS FOR ENHANCING ALCOHOL TOLERANCE IN YEAST |
AU2018336128B2 (en) | 2017-09-19 | 2023-01-05 | Tropic Biosciences UK Limited | Modifying the specificity of plant non-coding RNA molecules for silencing gene expression |
WO2019094595A2 (en) | 2017-11-09 | 2019-05-16 | Pinteon Therapeutics Inc. | Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies |
IL255664A0 (en) | 2017-11-14 | 2017-12-31 | Shachar Idit | Hematopoietic stem cells with enhanced properties |
WO2019106671A1 (en) | 2017-11-29 | 2019-06-06 | Ramot At Tel-Aviv University Ltd. | Methods of preventing or treating neurogenic shock |
WO2019106667A1 (en) | 2017-11-29 | 2019-06-06 | Weedout Ltd. | Compositions, kits and methods for controlling weed of the amaranthus genus |
EP3716993A1 (en) | 2017-12-03 | 2020-10-07 | Yeda Research and Development Co. Ltd | Treatment of an ischemic heart disease |
WO2019116376A1 (en) | 2017-12-17 | 2019-06-20 | Yeda Research And Development Co. Ltd. | Cop9 signalosome (csn) complex modulators and uses thereof |
EP3731965A1 (en) | 2017-12-28 | 2020-11-04 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Method to reproduce circadian rhythms on a microfluidic chip |
IL257225A (en) | 2018-01-29 | 2018-04-09 | Yeda Res & Dev | Treatment of sarcoma |
IL257269A (en) | 2018-01-31 | 2018-04-09 | Olender Tsviya | Signaling is directed to the endoplasmic reticulum |
EP3749368A1 (en) | 2018-02-08 | 2020-12-16 | Yeda Research and Development Co. Ltd | Methods of identifying and using agents for treating diseases associated with intestinal barrier dysfunction |
WO2019155459A1 (en) | 2018-02-08 | 2019-08-15 | Yeda Research And Development Co. Ltd. | Inhibitors of the 20s proteasome |
WO2019162945A1 (en) | 2018-02-23 | 2019-08-29 | Carmel Haifa University Economic Corporation Ltd. | Methods for treating memory impairment and cognitive dysfunction |
US20200408761A1 (en) | 2018-02-28 | 2020-12-31 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | Methods of diagnosing and treating bladder cancer |
WO2019175869A1 (en) | 2018-03-12 | 2019-09-19 | Yeda Research And Development Co. Ltd | Treatment of a heart disease |
CN112236131A (zh) | 2018-03-29 | 2021-01-15 | 技术研究及发展基金有限公司 | 包含pten抑制剂的囊泡及其用途 |
IL258467A (en) | 2018-03-29 | 2018-07-04 | Ilana Kolodkin Gal | Methods of disrupting a biofilm and/or preventing formation of same |
EP3774047A1 (en) | 2018-03-29 | 2021-02-17 | Yeda Research and Development Co. Ltd | Use of electric field gradients to control gene expression |
GB201807192D0 (en) | 2018-05-01 | 2018-06-13 | Tropic Biosciences Uk Ltd | Compositions and methods for reducing caffeine content in coffee beans |
IL259392A (en) | 2018-05-15 | 2018-08-01 | Yeda Res & Dev | Vaccination with cancer neo-antigens |
WO2019220441A1 (en) | 2018-05-15 | 2019-11-21 | Hadasit Medical Research Services And Development Ltd. | Compositions and methods for treating cancer resistant to an anti-cancer agent |
US20210121491A1 (en) | 2018-05-27 | 2021-04-29 | Biolinerx Ltd. | Agi-134 combined with a checkpoint inhibitor for the treatment of solid tumors |
US11827892B2 (en) | 2018-06-07 | 2023-11-28 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Nucleic acid constructs and methods of using same |
CN112384063A (zh) | 2018-06-07 | 2021-02-19 | 以色列国家农业部、农村发展农业研究组织·沃尔卡尼中心 | 再生及转殖大麻的方法 |
EP3810636A1 (en) | 2018-06-25 | 2021-04-28 | Yeda Research and Development Co. Ltd | Systems and methods for increasing efficiency of genome editing |
WO2020008412A1 (en) | 2018-07-04 | 2020-01-09 | Ukko Inc. | Methods of de-epitoping wheat proteins and use of same for the treatment of celiac disease |
US20210269860A1 (en) | 2018-07-08 | 2021-09-02 | Yeda Research And Development Co. Ltd. | Person-specific assessment of probiotics responsiveness |
WO2020012486A1 (en) | 2018-07-11 | 2020-01-16 | Kahr Medical Ltd. | SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF |
JP7395517B2 (ja) | 2018-07-11 | 2023-12-11 | イミュニティ ファルマ リミテッド | ペプチド化合物およびその治療的用途 |
AU2019315054A1 (en) | 2018-07-31 | 2021-03-18 | Collplant Ltd. | Tobacco transgenic event and methods for detection and use thereof |
IL261156A (en) | 2018-08-14 | 2020-02-27 | Fass Deborah | Chimeric quiescin sulfhydryl oxidase (qsox1) antibodies and uses of same |
CA3108434A1 (en) | 2018-08-24 | 2020-02-27 | Yeda Research And Development Co. Ltd. | Methods of modulating m2 macrophage polarization and use of same in therapy |
CN113038951B (zh) | 2018-09-20 | 2024-04-30 | 耶达研究及发展有限公司 | 治疗肌萎缩侧索硬化的方法 |
WO2020065647A1 (en) | 2018-09-25 | 2020-04-02 | Biolinerx Ltd. | Methods of selecting treatment for cxcr4-associated cancer |
IL262658A (en) | 2018-10-28 | 2020-04-30 | Memorial Sloan Kettering Cancer Center | Prevention of age related clonal hematopoiesis and diseases associated therewith |
IL263184A (en) | 2018-11-21 | 2020-05-31 | Yarden Yosef | Method of treating cancer and compositions for same |
EP3914698A1 (en) | 2019-01-23 | 2021-12-01 | Yeda Research and Development Co. Ltd | Culture media for pluripotent stem cells |
IL264768A (en) | 2019-02-10 | 2020-08-31 | Sagi Irit | ANTI-MATRIX METALLOPROTEINASE 7 (MMP-7) inhibitory antibody and its use |
IL264854A (en) | 2019-02-14 | 2020-08-31 | Bahat Anat | Spt5 inhibitors and methods of use thereof |
EP3927807A1 (en) | 2019-02-21 | 2021-12-29 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. | Methods of generating organoids for high throughput screening of drugs |
JP2022521010A (ja) | 2019-02-21 | 2022-04-04 | イッスム・リサーチ・デベロプメント・カムパニー・オブ・ザ・ヘブリュー・ユニバシティー・オブ・エルサレム リミテッド | 薬物誘導性腎毒性を減少させるための方法 |
MX2021010611A (es) | 2019-03-05 | 2021-11-12 | The State Of Israel Ministry Of Agriculture & Rural Development Agricultural Res Organization Aro Vo | Aves con genoma editado. |
EP3938400A4 (en) | 2019-03-11 | 2022-11-23 | Memorial Sloan Kettering Cancer Center | CD22 ANTIBODIES AND METHODS OF USE THEREOF |
GB201903520D0 (en) | 2019-03-14 | 2019-05-01 | Tropic Biosciences Uk Ltd | Modifying the specificity of non-coding rna molecules for silencing genes in eukaryotic cells |
GB201903519D0 (en) | 2019-03-14 | 2019-05-01 | Tropic Biosciences Uk Ltd | Introducing silencing activity to dysfunctional rna molecules and modifying their specificity against a gene of interest |
GB201903521D0 (en) | 2019-03-14 | 2019-05-01 | Tropic Biosciences Uk Ltd | No title |
IL265486A (en) | 2019-03-19 | 2020-09-30 | Yeda Res & Dev | Bistable type ii opsins and uses thereof |
WO2020194317A1 (en) | 2019-03-28 | 2020-10-01 | Yeda Research And Development Co. Ltd. | Method of treating lipid-related disorders |
WO2020202142A2 (en) | 2019-03-31 | 2020-10-08 | Yeda Research And Development Co. Ltd. | Anti-viral and anti-tumoral compounds |
IL266433B (en) | 2019-05-02 | 2020-11-30 | Sagi Irit | Compositions comprising the propeptide of lysyl oxidase and uses thereof |
US20220220559A1 (en) | 2019-05-13 | 2022-07-14 | Yeda Research And Development Co. Ltd. | Cell-free mirna biomarkers for prognosis and diagnosis of neurodegenerative diseases |
IL266728B (en) | 2019-05-19 | 2020-11-30 | Yeda Res & Dev | Identification of recurrent mutant neopeptides |
US20220213445A1 (en) | 2019-05-22 | 2022-07-07 | Hadasit Medical Research Services And Development Ltd. | Methods of culturing human pluripotent cells |
CA3140406A1 (en) | 2019-05-28 | 2020-12-03 | Shanghaitech University | Composition and methods to treat ectodermal dysplasia 2, clouston type |
JP2022536326A (ja) | 2019-06-12 | 2022-08-15 | ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド | オリゴデンドロサイトの産生方法 |
WO2020255124A1 (en) | 2019-06-16 | 2020-12-24 | Yeda Research And Development Co. Ltd. | Method for stabilizing intracellular rna |
WO2020261281A1 (en) | 2019-06-27 | 2020-12-30 | Ramot At Tel-Aviv University Ltd. | Semaphorin 3a antibodies and uses thereof |
EP3994268A1 (en) | 2019-07-04 | 2022-05-11 | Ukko Inc. | De-epitoped alpha gliadin and use of same for the management of celiac disease and gluten sensitivity |
JP2022541742A (ja) | 2019-07-11 | 2022-09-27 | カール メディカル リミテッド | ヘテロダイマーおよびその使用方法 |
US20220281960A1 (en) | 2019-07-16 | 2022-09-08 | Ramot At Tel-Aviv University Ltd. | Compositions and methods for the treatment of tuberculosis |
IL268111A (en) | 2019-07-16 | 2021-01-31 | Fainzilber Michael | Methods of treating pain |
CA3147575A1 (en) | 2019-07-29 | 2021-02-04 | Yeda Research And Development Co. Ltd. | Methods of treating and diagnosing lung cancer |
EP4004212A1 (en) | 2019-07-30 | 2022-06-01 | The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Institute) | Methods of controlling cannabinoid synthesis in plants or cells and plants and cells produced thereby |
EP4014046A1 (en) | 2019-08-12 | 2022-06-22 | Yeda Research and Development Co. Ltd | Dna repair blood test for predicting response of lung cancer patients to immunotherapy |
US20240140988A1 (en) | 2019-08-22 | 2024-05-02 | Ariel Scientific Innovations Ltd. | Scaled-up methods for purifying antibodies |
EP4021463A1 (en) | 2019-08-27 | 2022-07-06 | Yeda Research and Development Co. Ltd | Treatment of bacterial vaginosis |
WO2021048852A1 (en) | 2019-09-11 | 2021-03-18 | Yeda Research And Development Co. Ltd. | Methods of treating breast cancer |
IL269674B (en) | 2019-09-25 | 2020-08-31 | Roy Bar Ziv | Assembling protein complexes on a chip |
IL270306A (en) | 2019-10-30 | 2021-05-31 | Yeda Res & Dev | Prevention and treatment of pre-myeloid and myeloid malignancies |
WO2021084526A1 (en) | 2019-10-31 | 2021-05-06 | Yeda Research And Development Co. Ltd. | Engineered autotrophic bacteria for co2 conversion to organic materials |
MX2022005678A (es) | 2019-11-11 | 2022-10-18 | Ibi Ag Innovative Bio Insecticides Ltd | Nanocuerpos para el control de insectos y usos de los mismos. |
WO2021100034A1 (en) | 2019-11-19 | 2021-05-27 | Protalix Ltd. | Removal of constructs from transformed cells |
IL270800A (en) | 2019-11-20 | 2021-05-31 | Yeda Res & Dev | A method for treating Alzheimer's disease |
EP4077731A1 (en) | 2019-12-22 | 2022-10-26 | Yeda Research and Development Co. Ltd | Diagnosis of frontotemporal dementia |
IL271656A (en) | 2019-12-22 | 2021-06-30 | Yeda Res & Dev | System and methods for identifying cells that have undergone genome editing |
IL271778A (en) | 2019-12-31 | 2021-06-30 | Ichilov Tech Ltd | Methods for treating atopic dermatitis |
WO2021137230A1 (en) | 2019-12-31 | 2021-07-08 | Kahr Medical Ltd. | Methods of culturing t cells and uses of same |
WO2021137231A1 (en) | 2019-12-31 | 2021-07-08 | Kahr Medical Ltd. | Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same |
IL272074B1 (en) | 2020-01-15 | 2024-08-01 | Immunity Pharma Ltd | Peptide compounds and their use in methods of treating diseases |
IL272194A (en) | 2020-01-22 | 2021-07-29 | Yeda Res & Dev | Multi-target antibodies for use in the treatment of diseases |
WO2021152584A1 (en) | 2020-01-28 | 2021-08-05 | Ariel Scientific Innovations Ltd. | Methods of analyzing cell membranes |
IL272389A (en) | 2020-01-30 | 2021-08-31 | Yeda Res & Dev | Kits containing antibodies to PD-L1 and their uses in therapy |
EP4096647A1 (en) | 2020-01-30 | 2022-12-07 | Yeda Research and Development Co. Ltd | Treating acute liver disease with tlr-mik inhibitors |
IL272390A (en) | 2020-01-30 | 2021-08-31 | Yeda Res & Dev | Cancer treatment methods |
WO2021152586A1 (en) | 2020-01-30 | 2021-08-05 | Yeda Research And Development Co. Ltd. | Methods of analyzing microbiome, immunoglobulin profile and physiological state |
KR20220151168A (ko) | 2020-02-09 | 2022-11-14 | 엔엘씨 파르마 엘티디 | Sars-cov-2에 대한 신속한 검출 테스트 |
IL272586A (en) | 2020-02-10 | 2021-08-31 | Yeda Res & Dev | A method for cell cluster analysis |
WO2021173674A1 (en) | 2020-02-26 | 2021-09-02 | A2 Biotherapeutics, Inc. | Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof |
US20230127559A1 (en) | 2020-03-16 | 2023-04-27 | Yeda Research And Development Co. Ltd. | Peptide analogs and use of same in treating diseases, disorders or conditions associated with mutant p53 protein |
AU2021245409A1 (en) | 2020-03-29 | 2022-11-24 | Yeda Research And Development Co. Ltd. | Variants of beta-glucocerebrosidase for use in treating Gaucher Disease |
IL296698A (en) | 2020-03-31 | 2022-11-01 | Biomuse Ltd | Bacteria for the prevention and treatment of smoking damage to the lungs |
EP4133107A1 (en) | 2020-04-06 | 2023-02-15 | Yeda Research and Development Co. Ltd | Methods of diagnosing cancer and predicting responsiveness to therapy |
EP4132479A1 (en) | 2020-04-07 | 2023-02-15 | Ramot at Tel-Aviv University Ltd. | Cannabidiol-containing compositions and uses thereof |
IL297228A (en) | 2020-04-13 | 2022-12-01 | Exoprother Medical Ltd | Cellular vesicles containing non-mutant p53 for antiviral therapy |
US20210322483A1 (en) | 2020-04-16 | 2021-10-21 | Ichilov Tech Ltd. | Cell-derived particles presenting heterologous cd24 and use thereof in therapy |
WO2021229577A1 (en) | 2020-05-12 | 2021-11-18 | Collplant Ltd. | Collagen as a delivery tool for metal-based anti-viral agents |
IL274811B (en) | 2020-05-20 | 2021-05-31 | Yeda Res & Dev | Spatial information is developed for the analysis of individual cells |
IL299276A (en) | 2020-06-22 | 2023-02-01 | Univ Ramot | Protein modules with cell subunits that express them and their uses |
US20230293530A1 (en) | 2020-06-24 | 2023-09-21 | Yeda Research And Development Co. Ltd. | Agents for sensitizing solid tumors to treatment |
IL276599A (en) | 2020-08-09 | 2022-03-01 | Yeda Res & Dev | T cell receptor unique to mage-a1 and its uses |
IL276627A (en) | 2020-08-10 | 2022-03-01 | Yeda Res & Dev | Compositions for diagnosis and treatment of coronavirus infections |
EP4199703A1 (en) | 2020-08-18 | 2023-06-28 | International Rice Research Institute | Methods of increasing outcrossing rates in gramineae |
IL277488A (en) | 2020-09-21 | 2022-04-01 | Yeda Res & Dev | Weight regulation method |
IL301503A (en) | 2020-09-23 | 2023-05-01 | Yeda res & development co ltd | Methods and preparations for the treatment of the disease caused by the corona virus |
IL277743A (en) | 2020-10-01 | 2022-04-01 | Yeda Res & Dev | A method for diagnosing breast cancer |
JP2023545999A (ja) | 2020-10-05 | 2023-11-01 | プロタリクス リミテッド | ダイサー(dicer)様ノックアウト植物細胞 |
WO2022074656A1 (en) | 2020-10-07 | 2022-04-14 | Protalix Ltd. | Long-acting dnase |
WO2022079719A1 (en) | 2020-10-15 | 2022-04-21 | Yeda Research And Development Co. Ltd. | Method of treating myeloid malignancies |
IL278401A (en) | 2020-10-29 | 2022-05-01 | Yeda Res & Dev | Polynucleotides for editing RNA and a method for using them |
WO2022097157A2 (en) | 2020-11-09 | 2022-05-12 | 1E Therapeutics, Ltd. | Catalytic sequence based methods of treating or preventing bacterial infections |
JP2023550979A (ja) | 2020-11-26 | 2023-12-06 | ウッコ インコーポレイテッド | 改変された高分子量グルテニンサブユニット及びその使用 |
IL279559A (en) | 2020-12-17 | 2022-07-01 | Yeda Res & Dev | Controlling the ubiquitination process of mlkl for disease treatment |
IL304068A (en) | 2020-12-28 | 2023-08-01 | 1E Therapeutics Ltd | DNA enzymes against p21 messenger RNA |
IL304047A (en) | 2020-12-28 | 2023-08-01 | 1E Therapeutics Ltd | Silencing target sites in the p21 mRNA sequence |
EP4274886A2 (en) | 2021-01-10 | 2023-11-15 | Supermeat the Essence of Meat Ltd. | Pluripotent stem cell aggregates and microtissues obtained therefrom for the cultured meat industry |
US20240083843A1 (en) | 2021-01-14 | 2024-03-14 | Yeda Research And Development Co. Ltd. | Methods of producing vitamin d |
IL280340B (en) | 2021-01-21 | 2022-04-01 | Yeda Res & Dev | Antibodies, peptides and their combinations for the treatment and prevention of corona virus infections |
JP2024506955A (ja) | 2021-02-18 | 2024-02-15 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | ワクチンを作製する方法 |
JP2024506954A (ja) | 2021-02-18 | 2024-02-15 | イェダ リサーチ アンド デベロップメント カンパニー リミテッド | ワクチン作製用の遺伝子改変細菌 |
IL281561A (en) | 2021-03-16 | 2022-10-01 | Yeda Res & Dev | Methods and devices for growing mouse embryos outside the uterus |
CA3213424A1 (en) | 2021-03-30 | 2022-10-06 | Lior Moshe ZELCBUCH | Pseudomonas bacteriophage and uses thereof |
IL282188A (en) | 2021-04-08 | 2022-11-01 | Yeda Res & Dev | Combined use of ketamine and bretigabine for the treatment of psychiatric disorders |
EP4337764A1 (en) | 2021-05-12 | 2024-03-20 | Biomx Ltd. | Staphylococcus bacteriophage and uses thereof |
IL283563A (en) | 2021-05-30 | 2022-12-01 | Yeda Res & Dev | Profiling of amps for the diagnosis, monitoring and treatment of microbiome-related diseases |
CA3219233A1 (en) | 2021-06-06 | 2022-12-15 | Ravid STRAUSSMAN | Combined treatment for cancer |
JP2024534404A (ja) | 2021-06-13 | 2024-09-20 | イッスム・リサーチ・デベロプメント・カムパニー・オブ・ザ・ヘブリュー・ユニバシティー・オブ・エルサレム リミテッド | ヒト細胞を再プログラミングする方法 |
MX2023015233A (es) | 2021-06-16 | 2024-01-31 | Seedx Tech Inc | Metodos de clasificacion de semillas de matthiola. |
NL2028466B1 (en) | 2021-06-16 | 2022-12-21 | Sakata Holland B V | Methods of sorting matthiola seeds |
WO2023275255A1 (en) | 2021-07-02 | 2023-01-05 | Tropic Biosciences UK Limited | Delay or prevention of browning in banana fruit |
CN117980470A (zh) | 2021-07-18 | 2024-05-03 | 盖米达细胞有限公司 | 治疗性nk细胞群 |
WO2023002492A1 (en) | 2021-07-22 | 2023-01-26 | Yeda Research And Development Co. Ltd. | Codon optimization of nucleic acids |
WO2023012584A2 (en) | 2021-08-03 | 2023-02-09 | Genicity Limited | Engineered tcr complex and methods of using same |
EP4130028A1 (en) | 2021-08-03 | 2023-02-08 | Rhazes Therapeutics Ltd | Engineered tcr complex and methods of using same |
WO2023018621A1 (en) | 2021-08-10 | 2023-02-16 | Gamida-Cell Ltd. | Engineered nk cells, methods of their production and uses thereof |
GB202112865D0 (en) | 2021-09-09 | 2021-10-27 | Tropic Biosciences Uk Ltd | Resistance to black sigatoka disease in banana |
GB202112866D0 (en) | 2021-09-09 | 2021-10-27 | Tropic Biosciences Uk Ltd | Resistance to fusarium wilt in a banana |
IL286430A (en) | 2021-09-14 | 2023-04-01 | Yeda Res & Dev | Multispecific antibodies for use in the treatment of diseases |
CN118696122A (zh) | 2021-12-08 | 2024-09-24 | 耶达研究及发展有限公司 | 用于肺再生的多能肺祖细胞 |
WO2023209708A1 (en) | 2022-04-25 | 2023-11-02 | Yeda Research And Development Co. Ltd. | Compositions for altering cyclic adp-ribose secondary messenger signalling |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3654090A (en) * | 1968-09-24 | 1972-04-04 | Organon | Method for the determination of antigens and antibodies |
US3652761A (en) * | 1969-09-04 | 1972-03-28 | Corning Glass Works | Immunochemical composites and antigen or antibody purification therewith |
-
1970
- 1970-12-28 NL NL707018838A patent/NL154599B/xx not_active IP Right Cessation
-
1971
- 1971-12-10 US US00206952A patent/US3839153A/en not_active Expired - Lifetime
- 1971-12-13 CA CA129,950A patent/CA964560A/en not_active Expired
- 1971-12-13 ZA ZA718332A patent/ZA718332B/xx unknown
- 1971-12-15 IL IL38371A patent/IL38371A/xx unknown
- 1971-12-16 AU AU36986/71A patent/AU467394B2/en not_active Expired
- 1971-12-17 GB GB5873871A patent/GB1348938A/en not_active Expired
- 1971-12-22 FR FR7146179A patent/FR2120835A5/fr not_active Expired
- 1971-12-23 IT IT54975/71A patent/IT965020B/it active
- 1971-12-23 FI FI3669/71A patent/FI54034C/fi active
- 1971-12-23 SE SE7116552A patent/SE398557B/xx unknown
- 1971-12-23 AT AT1108971A patent/AT320145B/de not_active IP Right Cessation
- 1971-12-23 BR BR8553/71A patent/BR7108553D0/pt unknown
- 1971-12-24 CH CH1892971A patent/CH557030A/xx not_active IP Right Cessation
- 1971-12-26 EG EG552/71A patent/EG11604A/xx active
- 1971-12-27 BE BE777309A patent/BE777309A/nl not_active IP Right Cessation
- 1971-12-27 JP JP724140A patent/JPS5834783B1/ja active Pending
- 1971-12-27 ES ES398372A patent/ES398372A1/es not_active Expired
- 1971-12-27 DE DE19712164768 patent/DE2164768B2/de not_active Ceased
- 1971-12-28 DK DK639871A patent/DK150690C/da active
-
1982
- 1982-11-02 JP JP57193265A patent/JPS58117455A/ja active Pending
- 1982-11-02 JP JP57193266A patent/JPS58117456A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
ES398372A1 (es) | 1975-06-16 |
DK150690C (da) | 1988-06-06 |
IL38371A (en) | 1974-06-30 |
GB1348938A (en) | 1974-03-27 |
AT320145B (de) | 1975-01-27 |
ZA718332B (en) | 1972-09-27 |
DE2164768A1 (de) | 1972-07-20 |
FI54034C (fi) | 1978-09-11 |
FI54034B (fi) | 1978-05-31 |
US3839153A (en) | 1974-10-01 |
JPS58117456A (ja) | 1983-07-13 |
BE777309A (nl) | 1972-04-17 |
CA964560A (en) | 1975-03-18 |
IT965020B (it) | 1974-01-31 |
SE398557B (sv) | 1977-12-27 |
NL154599B (nl) | 1977-09-15 |
DE2164768B2 (de) | 1976-01-22 |
AU467394B2 (en) | 1975-11-27 |
AU3698671A (en) | 1973-06-21 |
CH557030A (de) | 1974-12-13 |
NL7018838A (da) | 1972-06-30 |
IL38371A0 (en) | 1972-02-29 |
JPS5834783B1 (da) | 1983-07-28 |
JPS58117455A (ja) | 1983-07-13 |
EG11604A (en) | 1977-08-15 |
FR2120835A5 (da) | 1972-08-18 |
BR7108553D0 (pt) | 1973-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK150690B (da) | Fremgangsmaade og analysepakke til bestemmelse af en komponent i reaktionen mellem et specifikt binder-protein og det tilsvarende bindelige stofved enzym-immunoanalyse | |
USRE31006E (en) | Process for the demonstration and determination of reaction components having specific binding affinity for each other | |
US3850752A (en) | Process for the demonstration and determination of low molecular compounds and of proteins capable of binding these compounds specifically | |
US4828985A (en) | Antibodies against the complex of a small molecule and its binding protein, their preparation and their use in diagnostic methods | |
US3791932A (en) | Process for the demonstration and determination of reaction components having specific binding affinity for each other | |
US4235960A (en) | Competitive enzyme-linked immunoassay | |
USRE29169E (en) | Process for the demonstration and determination of reaction components having specific binding affinity for each other | |
US4232001A (en) | Methods and materials for detection of estrophilin | |
US4427781A (en) | Particle agglutination immunoassay with agglutinator for determining haptens; PACIA | |
US4477576A (en) | Antigen assay method and kit | |
HOSODA et al. | Effect of bridge heterologous combination on sensitivity in enzyme immunoassay for cortisol | |
US4621048A (en) | Reagents containing an anti-ligand bound to an anti-enzyme and methods for employing said reagents in an immunoassy | |
EP0383313A2 (en) | Reagent for immunoassay, and kit containing the same | |
EP0124366A2 (en) | Method of measuring biological ligands | |
Mariotti et al. | A new solid phase immunoradiometric assay for antithyroid microsomal antibody | |
US4693969A (en) | Reagent for use in a sandwich solid-phase enzyme-immunoassay and process for employing same | |
US6555388B1 (en) | Binding protein capture assay | |
JPH0731191B2 (ja) | チログロブリンを使用する甲状腺ホルモンの免疫定量法 | |
US9891214B2 (en) | Immunological assay method | |
EP0554458B1 (en) | Immunoassay and monoclonal antibody for determining diarrheal shellfish poisons | |
JPH081436B2 (ja) | 生物学的液体中の遊離リガンドの測定方法および測定用キット | |
EP0338045B1 (en) | Solid-phase non-separation enzyme assay | |
Dericks-Tan et al. | Pseudohypergonadotropinemia and pseudohyperprolactinemia induced by heterophilic antibodies? | |
Read et al. | Experiences with the haemagglutination method of human growth hormone assay | |
EP0390870A1 (en) | Method for detection of premenstrual syndrome |